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ABSTRACT 
Drug abuse is an escalating problem prevalent in both large metropolitan and rural 
places and is a major cause of mortality and morbidity all over the world.  Drugs of abuse 
such as morphine and nicotine are consumed by people for prolonged periods of times to 
improve their physical and mental condition as well as to get relief from pain and other 
medical conditions. This prolonged intake often overlaps with the clinical regimen of 
several chronic neuropsychological, cardiovascular, pulmonary, infectious and neoplastic 
diseases. One in four patients living with human immunodeficiency virus (HIV) infection 
reported use of drugs of abuse. Achieving target intracellular concentrations during long 
term therapy of several diseases can be challenging due to number of factors such as poor 
adherence, drug resistance and drug-drug interactions. One important mechanism of 
multidrug resistance involves the up-regulation of multidrug resistance transporter, p-
glycoprotein (p-gp), member of ATP binding cassette (ABC) superfamily that effluxes 
most of the therapeutic drugs and reduce their intracellular accumulation. Drug-drug 
interactions can result from inhibition and induction of the cytochrome P450 enzymes 
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and/or efflux transporters. Drugs of abuse have the ability to potentiate or attenuate the 
effects of co-administered therapeutic drugs that can lead to toxic effects or a reduction in 
the therapeutic activity of the co-administered drugs. This thesis investigates the chronic 
effect of morphine and nicotine on the expression and functional activity of efflux 
transporters (MDR1, MRP2, and BCRP) and metabolizing enzymes (CYP3A4). 
Induction of Pregnane-X-Receptor (PXR) was found to regulate the induction of MDR1 
and CYP3A4 gene expression.  Interactions between drugs of abuse and therapeutic 
drugs provide crucial insights into the failure of clinical regimen in patients suffering 
from HIV, cancer and other infections. Results from this thesis elucidate the mechanism 
behind the interactions between morphine and nicotine and HIV protease inhibitors. 
Studies were performed primarily through the use of in vitro models; e.g. LS180 and 
Caco-2 (for intestine) and HepG2 (for liver). 
In the second set of my studies, expression and functional activity of efflux 
transporters in Calu-3, human airway epithelial cell line was investigated. Expression and 
functionality of efflux and influx transporters in the airways is poorly identified and 
characterized. Results from this project allow understanding of the drug absorption in 
airways. As part of the study, molecular and functional activity of breast cancer 
resistance protein was identified for the first time. Folic acid receptor-alpha and proton 
coupled folic acid transporter expression was identified at molecular and protein level 
across human bronchial epithelial cell line, Calu-3. Since nicotine is smoked through 
lungs, effect of nicotine on the expression and functional activity of efflux transporters 
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and metabolizing enzymes was determined. Nicotine was found to induce MDR1, BCRP 
expression and CYP3A4/A5 metabolism in Calu-3 cells.  Male Sprague Dawley rats were 
treated with nicotine to investigate the effect of nicotine on CYP3A4 mediated rat lung 
metabolism. Cortisol was used as a model substrate to evaluate CYP3A4 mediated 
metabolism. Cortisol metabolism enhanced in nicotine treated rats than control rats 
signifying the enhanced CYP3A4/A5 metabolism. Furthermore, cortisol metabolism 
enhanced in microsomes obtained from smokers when compared to microsomes obtained 
from non-smokers.   
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CHAPTER-1 
 
INTRODUCTION 
 
Overview 
            Drug abuse is an escalating problem prevalent in both large metropolitan and rural 
places and is a major cause of mortality and morbidity all over the world.  Drugs are 
abused by people for prolonged periods of time to improve their physical and mental 
condition as well as to get relief from pain and other medical conditions.  This prolonged 
intake often overlaps with the clinical regimen of several chronic neuropsychological, 
cardiovascular, pulmonary, infectious and neoplastic diseases. Global human 
immunodeficiency virus (HIV) epidemic continues to grow in many countries and abuse 
of tobacco, alcohol and illicit drugs poses a risk for HIV clinical regimens. Global 
estimates in 2013 indicate that approximately 34 million people were estimated to be 
living with HIV infection and one in four people living with HIV reported use of drugs of 
abuse. HIV protease inhibitors are the frontline drugs in the treatment of HIV infections 
and are routinely administered with non-nucleoside reverse transcriptase inhibitors and 
nucleoside reverse transcription inhibitors. Achieving target plasma concentrations during 
long term therapy can be challenging due to number of factors such as poor adherence, 
viral resistance and drug interactions. Also, patients receive therapy for prophylaxis of 
opportunistic infections such as pneumocystis pneumonia, tuberculosis infection, 
mycobacterium avium complex disease, bacterial respiratory disease, bacterial enteric 
infections, oropharyngeal and esophageal candidiasis and other diseases that are more 
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severe due to immunosuppression. These drug combinations result in drug-drug 
interactions and these primarily result from inhibition and induction of the cytochrome 
P450 enzymes and/or efflux transporters. HIV protease inhibitors are known to be 
substrates and inhibitors for efflux transporters such as MDR1, MRP2 and metabolizing 
enzymes such as CYP3A4. Kim et al. demonstrated that plasma concentrations of 
indinavir, nelfinavir, and saquinavir were elevated 2 to 5 fold in MDR knockout mice 
relative to wild-type mice after oral administration. Fitzsimmons et al reported that 
CYP3A4 mediated metabolism contributes to poor bioavailability of HIV protease 
inhibitors. Results from these studies indicate that P-gp and CYP3A4 can affect the 
disposition of HIV protease inhibitors resulting in lower efficacy. 
            Long term exposure to drugs of abuse can modulate the expression of efflux 
transporters and metabolizing enzymes and thereby alter the efficacy of the HIV therapy 
resulting in clinically significant drug interactions. These interactions may cause HIV 
patients to require a large dosage of drugs and therapeutic drug monitoring of these drugs 
is conducted to prevent sub-therapeutic or toxic concentrations. Short term exposure of 
mouse fibroblast NIH-3T3 cells with morphine induced p-glycoprotein expression. 
Further studies are needed to investigate the effect of chronic exposure of these drugs of 
abuse on the expression of efflux transporters and metabolizing enzymes. A classic 
example to this hypothesis involves the effect of long term treatment of rifampicin on HIV 
protease inhibitor ritonavir and saquinavir. HIV patients who are receiving long term 
therapy of Rifampicin will need higher doses of HIV protease inhibitors to maintain 
3 
 
adequate plasma concentrations. Efflux transporters such as MRP2 and BCRP also play a 
major role in the disposition of several therapeutic drugs. 
               Pulmonary infections are the main cause of morbidity in patients with HIV. HIV 
is frequently detected in lungs and alveolar macrophages have also been shown to be 
reservoirs for HIV disease. HIV infected persons are at increased risk of manifesting 
pulmonary conditions such as chronic obstructive pulmonary disease (COPD), lung 
cancer, and pulmonary arterial hypertension. Pulmonary delivery is an efficient non-
invasive route of delivery for the treatment of pulmonary and systemic diseases. Our 
understanding of pulmonary influx, efflux mechanisms and metabolism is very limited. 
Furthermore, recent studies have shown that HIV protease inhibitors are being studied 
extensively for their anticancer properties against lung cancer and pulmonary 
opportunistic infections. Expression and modulation of activity of efflux transporters, 
metabolizing enzymes and nuclear receptors is cell type specific.        
Therefore, role of efflux transporters and metabolizing enzymes in lungs needs to be 
investigated.            
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Statement of Problem 
            Resistance to chemotherapy remains a major challenge for physicians in the 
clinical management of life threatening infections such as HIV. Development of drug 
resistant HIV viruses after multiple drug administration ranging from months to years is 
frequently witnessed among HIV patients1. One of the main cause by which cells acquire 
drug resistance is the induction of efflux transporters and metabolizing enzymes. Increase 
of drug resistant viral load combined with therapeutic failure result in several deaths. 
Furthermore, co-administered drugs that can induce efflux transporters and metabolizing 
enzymes pose an additional risk for induction as well as therapeutic failure 2.  
             Drug abuse is one of the main public health problems in the world with an 
estimated 200 million people abusing drugs illegally and an estimated 1 million people 
live with HIV in United States3. Drugs of abuse such as nicotine and morphine can cause 
inhibition or induction of these efflux transporters and/or metabolizing enzymes. 
Inhibition of efflux transporters and metabolizing enzymes lead to toxicity whereas 
induction results in therapeutic failure.  Thus, drug interactions may compromise the 
safety and effectiveness of therapeutic medications4. 
              Failure to predict the induction potential of these drugs of abuse may lead to 
therapeutic failure of the administered drugs intended for HIV therapy.  This thesis aims to 
investigate the mechanism of drug-drug interactions between nicotine and morphine and 
HIV protease inhibitors. Chronic effects of nicotine and morphine on the expression and 
functional activity of efflux transporters (MDR1, BCRP, MRP2) and metabolizing 
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enzymes (CYP3A4) were determined. Induction mediated drug interactions are cell type 
specific and depend upon the expression and functional activity of efflux transporters, 
metabolizing enzymes and nuclear receptors5. Therefore, we aim to study the inductive 
effects of nicotine and morphine in in vitro model cell lines LS180, Calu-3 and HepG2 
and investigate the expression and functional activity of efflux transporters.  
 
Hypothesis 
             According to National Institute of Drug Abuse, approximately, 69.6 million 
people of ages 12 years or older reported current use of tobacco. Cigarette smoking kills 
an estimated 440,000 U.S citizens each year6. Nicotine in tobacco is highly addictive. 
Clinicians often ask their patients if they are smokers or nonsmokers.  It was observed 
clinically that pharmacokinetic profile of inhaled insulin is significantly affected owing to 
its higher concentrations in smokers than in nonsmokers. Smokers might need higher 
doses of medication than nonsmokers. Medications that interacts with smoking often 
needs dosage adjustment to achieve the therapeutic levels7.  Furthermore, cigarette 
smoking is contraindicated along with hormonal contraceptives and inhaled 
corticosteroids because of the increased risk of adverse cardiovascular effects. Morphine is 
the opioid of choice for moderate to severe cancer pain and is a substrate of p-
glycoprotein. Morphine has been shown to induce p-glycoprotein expression in rat brain. 
Studies utilizing p-glycoprotein knock out mouse models have shown that p-glycoprotein 
restricts the uptake of morphine into the brain. This study concluded that modulation of p-
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glycoprotein expression at the blood brain barrier by morphine has an impact on the 
central analgesic activity of morphine8. Increased uptake of morphine has been 
demonstrated in rats with the concomitant administration of GF120918, a known P-gp and 
BCRP inhibitor9. Also, rats treated with morphine for 5 days resulted in a 2 fold induction 
of p-glycoprotein expression in brain.          
            It has been demonstrated that MDR1 mRNA can be induced by short term 
exposure of some cytotoxic agents10. Such induction of MDR1 mRNA and further 
upregulation of p-glycoprotein levels leads to development of drug resistance. Drug 
delivery via inhalation is an alternative route of systemic administration. Also, drugs are 
delivered directly to lungs to treat life threatening diseases such as lung cancer. Lung is an 
important sanctuary organ for HIV replication and proliferation. During HIV infection, 
low viral RNA always exists in sanctuary sites such as lungs and brain. Lungs are one of 
the major targets during HIV infection and advanced complications of AIDS11. 
Opportunistic infections along with serious pulmonary complications are often observed 
in 50% of the HIV patients12. Moreover, p-glycoprotein expressed at the sanctuary sites 
limit the concentrations of therapeutic agents.  
 
Oral Delivery 
            HIV protease inhibitors have been successfully used to control disease progression 
in HIV-1 patients.  Clinical outcome of the therapy depends on the higher intracellular 
concentrations of HIV protease inhibitors in cells infected with HIV13. However, clinical 
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outcome of antiretroviral therapy often fails due to complex factors such as poor 
adherence, virological resistance, drug interactions and cellular resistance14. HIV protease 
inhibitors are known substrates of efflux transporters such as p-glycoprotein, MRP215 and 
metabolizing enzymes such as CYP3A416 at the intestinal barrier. Drugs of abuse such as 
morphine and nicotine may alter the expression and activity of these efflux transporters 
and metabolizing enzymes. Clinically significant interactions have been reported with the 
chronic administration of HIV protease inhibitors with drugs that are substrates for 
CYP3A4. For example, chronic administration of ritonavir increases the oral clearance of 
methadone, phenytoin and ethinyl estradiol17. Furthermore, PXR has been shown to play a 
major role in the induction of efflux transporters and metabolizing enzymes. Drugs which 
activate PXR levels may induce CYP3A4 expression and activity18. Three mechanisms 
involved in drug-drug interactions are depicted in figure-2.1. 
 
Figure 2.1  Mechanism of drug-drug interactions 
8 
 
Pulmonary Delivery 
             Pulmonary delivery provides a noninvasive alternative mode of delivery to 
subcutaneous as well as intravenous route. FDA approved several drugs for treating 
respiratory and pulmonary conditions such as allergy, asthma, bronchitis, cystic fibrosis, 
emphysema, lung disease and others19.  Inhaled drugs market was estimated to reach to $ 
44 billion by 2016 and the pulmonary market is considered to be the fourth largest 
therapeutic area in pharmaceutical sales. Lungs offer number of physiological benefits 
such as larger surface area, thin barrier and high vascularization) for drug delivery when 
compared to other routes.  Drugs are inhaled through the lungs and enter the blood stream 
the alveolar epithelium. Drug transporter proteins are important determinants in drug 
disposition and response with subsequent effect on the pharmacokinetics of drugs. Also, 
metabolizing enzymes and influx transporters play an important role in the modulation of 
the permeability of the drugs across alveolar epithelium.  P-glycoprotein and MRP1 
expression in human lung suggests the protective role of these transporters against 
exogenous toxic substances entering from the air and blood stream. Scheffer et al detected 
higher expression of p-glycoprotein in lungs of mice20. P-glycoprotein kinetics was 
measured by measuring lipophilic amine dye rhodamine 6G in intact lung. This study 
showed higher rhodamine 6G accumulation in the presence of p-gp inhibitors Verapamil 
and GF12091821. Another multidrug resistance transporter MRP1 is highly expressed at 
the basolateral side of the human bronchial epithelial cells. Lehmann et al detected high 
MRP1 expression in normal human lung22. Functional activity of MRP1 was also detected 
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in Calu-3 cells in human bronchial epithelial cell line23. BCRP protein levels are expressed 
in epithelial cell layers as well as endothelial blood capillaries suggesting its role in the 
protection of lungs against toxic compounds from the air and blood stream respectively24. 
Higher BCRP expression was found to correlate with poor clinical outcome of platinum 
based chemotherapy for advanced non-small cell lung cancer cells25. These studies depict 
the importance of efflux transporters in the distribution of pulmonary drugs to the site of 
action. Therefore, delivery of pulmonary drugs to the site of action may depend on the 
activity and expression of the efflux transporters and metabolizing enzymes. Little is 
known about the functional activity and modulation of these efflux transporters and 
metabolizing enzymes. 
             Majority of the inhaled toxicants pass through the respiratory tract, exposing 
pulmonary epithelium to higher concentrations than liver cells. Higher concentrations can 
contribute to significant metabolism in lungs. In the same way, higher concentrations of 
tobacco smoke can modulate the metabolism of CYP enzymes.  Several CYP enzymes are 
expressed in the lungs of mammals, but studies on their modulation are very limited. Thus, 
studies answering the lung specific activation of efflux transporters and metabolizing 
enzymes needs to be performed. Finding results for this study is more difficult in humans, 
therefore in vitro lung airway epithelial cell models were utilized for these studies.   
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Objectives 
With this background the objectives of this dissertation are: 
 To investigate the chronic effect of nicotine and morphine on expression and 
functional activity of efflux transporters and metabolizing enzymes and to 
study their contribution to the intracellular accumulation of HIV protease 
inhibitors.   
 
 To characterize the expression and functional activity of folic acid carriers in 
human bronchial epithelial cell line, Calu-3 
 To study the role of efflux transporters in human bronchial epithelial cell    
line, Calu-3 
 To characterize the molecular and functional activity of breast cancer 
resistance protein in human bronchial epithelial cells, Calu-3  
 To investigate the effect of chronic exposure to nicotine on the levels of efflux  
transporters and metabolic enzymes in Calu-3 and rat lungs 
 
 
 
 
 
 
 Figure-2.2 Flow chart depicting the objectives of this thesis
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CHAPTER-2 
LITERATURE REVIEW 
               Adverse drug reactions are one of the leading causes of death in the United 
States. Pharmacokinetic drug-drug interactions are responsible for 22% of adverse drug 
interactions26. According to National Institute of Health Sciences, drug interaction is 
defined by “The pharmacologic or clinical response to the administration of a drug 
combination different from that anticipated from the known effects of the two agents 
when given alone”. Pharmacological desired and undesired effects of a drug occur from 
concentrations at its site of action. Concentration of a drug at its site of action depends 
upon the systemic concentrations which are again governed by absorption, metabolism, 
distribution and elimination. Variations in systemic concentrations can either cause 
treatment failure of life threatening infections or adverse toxicities. Interactions are of 
particular concern for drugs with narrow therapeutic index27.   
Drug Interactions 
              Drug-drug interactions can be classified into pharmacokinetic, 
pharmacodynamic and pharmaceutical interactions. Pharmacokinetic interactions affect 
absorption, distribution, metabolism and excretion of a target drug (figure-2.3). 
Pharmacokinetic interactions are again divided into three subclasses: drug absorption, 
protein binding and drug metabolism interactions.  
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Figure 2.3  Simplified depiction of drug-drug interactions 
Inhibition Interactions 
Majority of drug interactions are attributed to alteration in pharmacokinetics of 
therapeutic drug of interest by concomitant drugs which are inhibitors of p-glycoprotein 
and \or CYP3A428. One of the classical examples is the drug interactions of cardiac 
glycosides which have a narrow therapeutic index. For example, verapamil, when 
administered at a dose of 160 mg, led to a 40% increase in the plasma concentration of 
digoxin, whereas verapamil 240 mg increased the plasma concentration of digoxin by 
60% to 80%. These data suggest a dose-dependent inhibition of P-gp when verapamil and 
digoxin are administered concomitantly29. When both the co-administered drugs are 
substrates of an efflux transporter and\or metabolizing enzymes, drug interactions are 
warranted. In addition, inhibition of multiple CYP enzymes and one or more transporters 
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can have a significant effect on therapy. Sedative effect of benzodiazepines can be 
increased or decreased upon co-administration with ethanol or caffeine respectively30.  
              Drugs get absorbed across the intestinal cellular membranes into the blood 
stream. Physico-chemical properties of the drug, formulation characteristics, food and 
gastric emptying affect the process of absorption31. Factors that alter the absorption have 
a profound effect on bioavailability of the drugs.  These factors could be especially 
significant if the therapeutic drugs are prodrugs that require metabolic activation to 
produce functional activity. For example, anticancer drugs are metabolically activated 
through first pass effect in the intestine and\or liver before they reach systemic 
circulation32. Decreased absorption of chlorambucil was reported in leukemia patients 
when the drug was administered in fed state rather than fasting state33. Fluoroquinolone 
antibiotics were prone to chelation with cations such as calcium and magnesium, thereby 
affecting the absorption34. 
Enzyme Inhibition 
               Majority of the drugs are metabolized to active or inactive metabolites in 
intestine and liver. Inhibition of efflux transporters and metabolizing enzymes can result 
in enhanced plasma concentrations. Ritonavir, a potent CYP3A4 inhibitor is commonly 
used as a pharmacological boost to enhance the bioavailability of other protease 
inhibitors such as lopinavir and saquinavir35. Grape juice has been shown to enhance the 
bioavailability of many therapeutic drugs such as calcium channel antagonists, 
benzodiazepines, HMG-CoA reductase inhibitors and cyclosporine. Chemical 
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constituents present in grape fruit juice such as  naringin, naringenin, quercetin and  
kaempferol are shown to have inhibitory effect on MDR1 and CYP3A436.  
 
Figure 2.4 Depiction of inhibition and induction drug-drug interactions 
 
Induction Interactions 
             Most of the clinically relevant drug-drug interactions are often mediated by the 
inhibition and induction of CYP3A4 (figure-2.4). CYP3A4 is the major route of 
elimination of majority of therapeutic drugs. Induction of mRNA levels of CYP enzymes 
result in higher protein levels followed by enhanced intestinal and hepatic enzyme 
activity. Increased metabolism can affect the drug bioavailability and systemic 
disposition leading to reduced efficacy. Thus, new therapeutic drug entities are screened 
for their metabolism data and their potential to induce CYP3A4 has become increasingly 
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important as part of preclinical studies. Rifampicin is a strong inducer of CYP3A4 and 
therefore, its co-administration with other prescription drugs can result in their sub-
therapeutic plasma levels and thereby can alter the clinical outcomes. Induction of efflux 
transporters such as MDR1, MRP2 and BCRP also play an important role on the oral 
bioavailability of therapeutic drugs.  For example, MDR1 gene expression was induced in 
human tumors after in vivo exposure to cytotoxic drug doxorubicin.  Number of studies 
in cultured cell lines has indicated that change in steady state mRNA levels was found to 
depend on two pathways, rate of synthesis and rate of degradation. Promoters of efflux 
transporters and metabolizing enzymes can be activated by heat shock, heavy metals, 
differentiating enzymes and several therapeutic drugs.  Also, activation of nuclear 
receptor PXR can regulate the expression of MDR1 and CYP3A4.  
Efflux Transporters 
             Overexpression of efflux transporters was found to be primary mechanism 
involved in the development of multi drug resistance37. Efflux transporters are energy 
dependent membrane proteins that actively efflux the drug out of the cells. ATP binding 
cassette proteins are a superfamily of proteins that mediate multi drug resistance through 
energy driven pumps. P-glycoprotein, multi drug resistance protein (MRP 1-6) and breast 
cancer resistance protein (BCRP) belonging to ABC superfamily have been identified 
and characterized. Even though, these efflux transporters belong to the same superfamily, 
they have different with respect to their structure and amino acid sequence38(figure-2.5). 
Drugs may cross the cell membrane by two methods: passive diffusion and carrier 
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transport. By passive diffusion, drugs cross the cellular membrane down a concentration 
gradient. Rate of permeation depends upon the concentration gradient across the 
membrane and solubility of the drug. Highly lipid soluble drugs can diffuse more easily 
across the membrane than highly polar drugs. Carrier mediated transport is divided into 
facilitated diffusion and active transport. By active transport, drugs cross the membrane 
against a concentration gradient with energy expenditure. In contrast, facilitated diffusion 
does not require energy for drug transfer39. Studies have identified that most of the 
therapeutic drugs are substrates, inhibitors and inducers of these efflux transporters 
(Table-1). They are localized and expressed in both normal and malignant cells and are 
involved in the transport of many substances including excretion of toxins from liver, 
kidneys and intestine. In addition, they limit the permeability of xenobiotics across blood-
placental barrier, blood-brain barrier and testis.     
                P-glycoprotein: MDR1 gene, also called as ABCB1 gene was originally 
identified through its ability to confer multidrug resistance in tumor cells. MDR1 encodes 
p-glycoprotein, a 170 KDa. plasma membrane protein and was first identified by Juliano 
and Ling in Chinese hamster ovary cells. P-glycoprotein is a member of adenosine 
triphosphate binding cassette (ABC) superfamily of energy dependent efflux pumps40.  P-
gp is expressed not only in tumor tissues but also in normal tissues such as intestine, 
lungs, liver, kidney and brain. P-gp actively effluxes a wide range of structurally and 
functionally unrelated substrates such as steroids, anticancer drugs, HIV protease 
inhibitors, antiemetics, antibiotics, histamine receptor antagonists, calcium channel 
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blockers and immunosuppressants41. P-glycoprotein has different roles in different 
tissues. 
 
Figure 2.5 Structure of efflux transporters 
P-glycoprotein has a protective role in eliminating xenobiotics and toxic substances by 
actively effluxing them across several barriers like blood brain barrier and blood 
placental barrier42. In liver, it plays an important role in drug elimination by effluxing the 
drugs to bile.  In vivo studies in mice have shown a significant change in 
pharmacokinetics of drugs when given simultaneously with specific p-gp inhibitors43. 
Also, MDR1 knockout mice had increased the cellular concentrations in tissues such as 
brain and liver44.  
                  MRP2: Cole et al (1992) discovered a second type of efflux proteins MRPs in 
cancer cells other than MDR145. MRP, an ATP dependent efflux transporter belongs to 
ABC superfamily of proteins. MRP, a 190 KDa membrane protein specifically transport 
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glutathione and glucuronide conjugated drugs. MRP family consists of 9 members and 
unlike p-gp and BCRP, MRPs are expressed in a polarized manner on either apical or 
basolateral side of the membrane46.   
                 Breast cancer resistance protein: Breast Cancer Resistance Protein (BCRP) 
was identified in a breast cancer derived cell line that showed drug resistance even in the 
presence verapamil (a potent P-gp inhibitor)47. Although this protein is not over 
expressed not only in breast cancer, but it is termed BCRP as it was first isolated from a 
breast cancer cell line. The same efflux pump was also identified in a mitoxantrone-
resistant human colon carcinoma cell line S1-M1–80 and hence this protein also received 
the name MXR48. BCRP/MXR is the second member of the G subfamily of ABC 
transporters. Under the recommendation of Human Gene Nomenclature Committee 
BCRP has been renamed to ABCG2. It is also referred to as ABCP (p stands for 
placenta), to signify its high levels of expression in that tissue. BCRP, MXR and ABCP 
are homologous proteins differing only in one or two amino acid sequence. BCRP 
structurally diverges from the other prominent ABC transporters. BCRP is a so called 
half transporter having only six transmembrane helices and only one nucleotide binding 
domain49. With the help of low resolution crystallography it has been shown that 
functional BCRP has a homodimeric structure50.  BCRP is a high efficiency efflux pump 
and has broad substrate specificity. A significant amount of expression has also been 
observed in normal human tissues. BCRP expression is significantly expressed in 
placenta, intestine and liver. 
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Table 1. Substrates of efflux transporters and metabolizing enzymes 
Drug Metabolism 
            Drug metabolism may have a profound effect on the pharmacokinetics of the 
drugs. Drug metabolism can be divided into two types: Phase І metabolism which 
involves the pharmacological activation or inactivation of the drug by oxidation, 
reduction, hydrolysis and cyclization reactions.  Phase ІІ metabolism involves 
conjugation of phase І products to highly polar endogenous substances51 (figure-2.6). 
CYPs are superfamily of enzymes found in the endoplasmic reticulum responsible for 
biotransformation of a wide range of xenobiotics. Cytochrome P450 enzymes are 
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responsible for pharmacological activation and detoxification of anticancer drugs such as 
doxorubicin, etoposide and ifosfamide52.  
 
Figure 2.6   Phase Ι and phase ΙΙ metabolism 
CYP3A enzymes are the most abundant cytochrome P450 dependent mixed function 
oxidase enzymes involved in the metabolism of wide variety of endogenous compounds 
and diverse xenobiotics53. CYP3A4 is widely distributed in human tissue, with about 
29% expressed in human liver. CYP3A4 and CYP3A5 accounts for 30-40% of the total 
CYP450 present in the liver and small intestine54.  There is a significant interindividual 
variability in the expression and activity of CYP3A4 due to environmental, genetic and 
physiological factors. Also, the nuclear receptor pathways such as PXR and CAR 
regulate the expression and functional activity of CYP3A455.    
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HIV Protease Inhibitors 
            AIDS (Acquired immune deficiency syndrome) is a serious pandemic disease of 
the human immune system caused by human immunodeficiency virus (HIV). An 
estimated 33.4 million people are living with HIV by the year 2009 and more than 25 
million people have died of AIDS since 1981.  HIV, a lentivirus is a member of retroviral 
family that primarily infects helper T cells, macrophages and dendritic cells56. This 
infection lowers the CD4+T cell count and thereby weakens the immune system leading 
to life threatening opportunistic infections.  Several antiretroviral agents have been used 
either as a single agent or in combination for the treatment of HIV infections57.  HIV 
infects T cells that carry CD4 antigen on their surface. After the fusion of virus to  host 
cellular membrane, the virus enters the cell and its RNA gets reverse transcribed to DNA 
by the enzyme reverse transcriptase. The Viral DNA then integrates itself into host cell 
DNA by the enzyme integrase. HIV protease cleaves the translated viral polyproteins into 
individual mature proteins. The virions formed by the assembly of viral RNA and 
proteins are then released to infect another healthy cell58. Treatment with HIV protease 
inhibitors significantly lowered the plasma viral RNA levels and the virus replication. 
Studies have shown that metabolism of HIV protease inhibitors is mediated by CYP3A 
enzymes. Since HIV protease inhibitors are proven to be substrates and inhibitors of 
efflux proteins and metabolizing enzymes, drugs of abuse taken simultaneously can lead 
to enhanced plasma concentrations resulting in toxic effects. On contrary, chronic intake 
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of drugs of abuse lead to HIV treatment failure due to decline in their plasma 
concentrations. 
 
Figure 2.7   HIV virus resistance 
HIV protease inhibitors inhibit the cleavage of gag-pol protein substrate leading to the 
release of structurally defective and functionally inactive virus particles (Figure- 2.7). 
They are also active against HIV-1 and HIV-2 viral strains59. HIV protease inhibitors 
have low oral bioavailability mainly due to limited absorption and first pass metabolism 
by CYP3A4 metabolizing enzymes. The main aim of therapy is to maintain plasma 
concentrations of these drugs above their minimum effective dose so that they can target 
the viral sanctuary sites and halt the replication. Several factors influence the 
bioavailability of these drugs60. Membrane efflux proteins, influx transporters, 
metabolizing enzymes and plasma proteins alter the absorption and disposition of these 
drugs. Ketoconazole has been shown to increase the AUC and Cmax of saquinavir by 3 
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fold and bioavailability by 67% respectively61. 
 
Drugs such as astemizole, terfenadine and 
cisapride are contraindicated to be given concomitantly because of the toxic effects 
associated with enhanced blood saquinavir concentrations caused by CYP inhibition62. 
On the other hand, rifampicin, a known CYP3A4 inducer reduces plasma concentrations 
of saquinavir by 80% and therefore it is contraindicated with saquinavir63. A 70 fold 
decrease in viral production in cells overexpressing p-gp and a 50 fold increase in cells 
overexpressing MRP1 compared with control is observed64. Nuclear receptors such as 
PXR, RXR and CAR play an important role in the induction of efflux proteins and 
metabolizing enzymes65.   
Drugs of Abuse 
            When drugs are taken in an inconsistent manner for a non-therapeutic effect, it is 
considered as drug abuse. Drug abuse has been termed as the primary preventable health 
problem in United States66. Drug abuse is a chronic relapsing disorder accounting for 
several deaths and cost up to $400 billion every year67. Intake of drugs of abuse changes 
the mental or physical functioning of a person and lead to addiction68. Drug abuse lead to 
two different conditions: tolerance and dependence. In case of tolerance, a person takes 
drugs in larger doses upon time to produce the same effect. Dependence refers to physical 
or psychological dependence of a person to a specific drug. Whenever the intake of 
abused drug is stopped, it leads to development of withdrawal symptoms such as tremors 
and vomiting (physical dependence) and depression (psychological dependence). 
Addictive drugs show short term symptoms such as euphoria, drowsiness, increased 
25 
 
motor and speech activity. Long term addiction lead to physical deterioration, psychiatric 
problems, accidents and intellectual problems69. Narcotic analgesics, stimulants, 
depressants, hallucinogens, cannabis and volatile solvents are some of the frequently 
abused drugs. According to National Institute of Drug Abuse (NIDA), morphine is 
classified under narcotic analgesics whereas nicotine is classified under stimulants. 
Figure-2.8 shows the structure of morphine and nicotine, two of the widely abused drugs.  
 
Morphine 
               Morphine, a narcotic drug is a phenanthrene alkaloid obtained from opium 
poppy. Morphine elicits its pharmacological actions by acting on opioid µ-receptor70. 
Morphine is a scheduled ІІ narcotic drug that possess an addiction forming ability71. 
Morphine can be injected, swallowed and smoked. Morphine is also used for pain relief 
used in different forms like tablets, capsules and injections. Morphine is metabolized 
primarily through glucuronidation pathway by conjugating with uridine diphosphate 
glucuronosyl transferase enzymes. Morphine is metabolized to morphine-6-glucuronide, 
which is a potent analgesic72. 
 
Figure 2.8   Structure of nicotine and morphine 
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Nicotine  
According to national institute of drug abuse research report, tobacco use kills at least 
half a million Americans each year73.  Nicotine is the main component present in tobacco 
that is responsible for addiction. Nicotine produces its effects by binding to acetylcholine 
receptors. Stimulation of the acetylcholine receptors triggers the release of dopamine 
responsible for the stimulant and dependence properties of nicotine74. When tobacco is 
smoked, it enters the blood stream through the lungs. But, when it is chewed or sniffed, it 
crosses the mucosal membranes and enters the blood stream. Long term addiction of 
nicotine leads to chronic lung disease, cardiovascular disease, stroke and cancer. With the 
enhanced knowledge at cellular and molecular level, several possible mechanisms of drug 
dependence have been elucidated. Interaction of these drugs at the receptor level and the 
intracellular pathways associated with these drugs has been studied75.  
 
Importance of Drug-Drug Interactions 
           The primary goal of antiretroviral therapy is to maintain suppressive levels of HIV 
protease inhibitors against the development of virus resistance. Drug levels are 
continuously monitored throughout the dosing period of HIV protease inhibitors to avoid 
viral replication and emergence of mutant viruses in sanctuary sites. For example, use of 
anti-tuberculosis drug rifampin decrease the serum concentrations of nevirapine76 by 20-
55%. Serum concentrations of indinavir, lopinavir and atazanavir were decreased by 
>90% when administered with ritonavir boosted dose in presence of rifampin. Therefore, 
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dosage adjustments were recommended necessitating high dose ritonavir boost as well as 
other HIV protease inhibitors77. As a result, hepatotoxicity was observed in HIV patients 
complicating the therapy. In view of these above situations, close therapeutic monitoring 
was recommended. Previous studies have shown that patients taking multiple drug 
combinations have their Cmin or Ctrough plasma concentrations below their IC50 during 
their dosing interval.  Bioavailability of saquinavir was significantly increased during the 
coadministration of ritonavir. This is mainly due to the limited absorption and higher 
intestinal and hepatic metabolism mediated by CYP3A enzymes78. Knockout mice 
studies suggested that p-glycoprotein mediated efflux play a significant role on the oral 
bioavailability of saquinavir79. Due to the overlapping and broad substrate specificity of 
p-glycoprotein and CYP3A4, drug-drug interactions involve both the enzyme and 
transport systems. Both CYP3A4 and p-gp are present at higher concentration in the 
villus enterocytes of small intestine, the primary site of absorption of orally administered 
drugs. (Figure-2.9)   
Models for Studying Induction 
             Enzyme induction refers to the up-regulation in the rate of enzyme synthesis 
from basal to a maximal level following the exposure to the drug. Enzyme induction is 
associated with the decrease in drug efficacy and in other cases, if the enzyme metabolite 
is toxic, enzyme induction results in cytotoxicity80. 
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Figure 2.9 Synergistic effects of p-glycoprotein and CYP3A4    
In vitro cell based models such as liver microsomes, primary hepatocytes, cryopreserved 
hepatocytes, reporter cell lines, recombinant cell lines, immortalized cells, precision cut 
liver slices have been developed to study human drug metabolism and induction of drug 
metabolizing enzymes in the liver81. Freshly isolated human hepatocytes are the primary 
in vitro model cell based systems used for studying drug metabolism. However, their 
utilization has been limited in industrial setting, due to unavailability. For this reason, 
cryopreserved human hepatocytes are most commonly employed to study the enzyme 
induction potential of new chemical entities. However, higher cost of these systems is the 
main disadvantage. For these studies, hepatocytes are cultured on multiwell plates and 
incubated with the drug of choice for the 72 hours. After the exposure, dose response 
activity and mRNA induction will be measured by adding a CYP specific probe. Along 
with these studies, immunoreactive protein and cell toxicity assays were also performed 
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to assess the transcriptional effect of the drug of choice on the hepatocytes. Subsequently, 
in vivo metabolic clearance of the drug can be predicted from the in vitro data82.   
 
Nuclear Receptors 
              Most common mechanism of CYP induction is transcriptional gene activation. 
Transcription factors such as PXR, CAR, RXR and AhR mediate the activation of drug 
metabolizing enzymes83. In general, nuclear receptors are associated with co-receptor 
complexes resulting in basal transcriptional levels. When a ligand enters the cytoplasm, it 
binds to the ligand binding domain of the nuclear receptor leading to conformational 
changes. Released co-receptors dimerize with other nuclear receptor partners resulting in 
chromatin modeling and subsequent transcriptional activation84(figure-2.10). 
 
 
Figure 2.10  PXR mediated CYP3A4 metabolism 
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The induction potential of drugs of abuse on HIV protease inhibitors was investigated by 
conducting in vitro experiments in LS180 cells, Caco-2 and HepG-2 cells. The results of 
in vitro studies elucidate the mechanism of drug-drug interactions. Morphine and 
morphine-6-glucuronide were proven to be substrates for p-glycoprotein. There are no 
reports on induction mechanism pathways of nicotine and morphine on the inhibition and 
induction of MDR1 and CYP3A4. Nicotine is a substrate for CYP2D6 and the effect on 
cellular permeability of HIV protease inhibitors85.  
Regulation of Gene Expression 
Efflux transporters mRNA can be induced by several factors such as heat shock, UV 
radiation, and chemotherapeutic agents. Despite the increase in mRNA levels, there is no 
increase in protein expression suggesting the translational control of gene expression86. 
Prolonged cellular exposure to cytotoxic agents has been reported to induce MDR1 gene 
expression through gene amplification as well as increased mRNA stability.  Studies 
investigating the relationship between mRNA, protein levels and functional activity of 
efflux transporters indicated contrasting reports. Taipalensuu et al used digoxin as a 
specific marker for MDR1 dependent drug efflux in Caco-2 cells and indicated that 
MDR1 mRNA transcript upregulation correlates with increase in MDR1 protein 
expression as well as functional activity87.      
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In Vitro Cell Models 
            In vitro cell models have led the way to design more efficient experiments to 
screen and to study the mechanisms of new chemical entities. Many pharmaceutical 
companies employ immortalized cell lines to study human drug metabolism and active 
transport of drugs. These in vitro cell lines have been able to predict efflux transporter 
and enzyme inhibition and induction to avoid potential clinical drug-drug interactions88.  
However, low and variable expression of efflux transporters and metabolizing enzymes 
pose an important challenge in the selection of in vitro model. Caco-2 and HepG2 cell 
lines have been employed to study intestinal drug absorption and hepatic drug absorption 
respectively89. Caco-2 cells were shown to express efflux transporters such as p-gp, 
MRP2 and BCRP. HepG2 cell lines express various liver specific metabolizing enzymes 
and transporters and are the most studied human hepatoma cell line90. Even though 
HepG2 is well characterized, this cell line shows undetectable and variable expression 
and activity of CYP91. Inducing agents such as 3-methylcholanthrene and rifampicin has 
been used to express higher levels of CYP92. LS-180, a microvillus expressing human 
colon carcinoma cell line is an excellent model cell line to study induction of CYP450 
and efflux transporters92.  Gupta et al has shown that LS-180 cell has been shown to 
enhance PXR mediated CYP3A4 expression when compared to HepG293(figure-2.11). 
Cell culture models of respiratory epithelium examine the mechanisms of drug delivery 
across alveolar and bronchial epithelium. Calu-3 cell line, derived from human bronchial 
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epithelial cell line has been extensively studied for drug delivery due to its ability to form 
tight monolayers94.   
 
 
Figure 2.11 Induction of CYP450 metabolizing enzymes mRNA expression in LS180 
cells 
 Calu-3 cells express p-glycoprotein and other metabolizing enzymes such as CYP1A1 
and CYP2B6. Other respiratory cell lines such as A549, an alveolar epithelial cell line 
lack the ability to generate high TEER in culture93. 
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CHAPTER-3 
 
TO INVESTIGATE THE CHRONIC EFFECT OF NICOTINE AND MORPHINE ON 
EXPRESSION AND FUNCTIONAL ACTIVITY OF EFFLUX TRANSPORTERS AND 
METABOLIZING ENZYMES AND TO STUDY THEIR CONTRIBUTION TO THE 
INTRACELLULAR ACCUMULATION OF HIV PROTEASE INHIBITORS  
Rationale 
               Development of multidrug resistance is a major obstacle to the treatment of life 
threatening diseases such as AIDS and cancer. One important mechanism of multidrug 
resistance involves the upregulation of multidrug resistance transporter, p-gp, that efflux 
the therapeutic drugs and decline their intracellular accumulation. Cigarette smoking 
alters the therapeutic response of respiratory drugs through several mechanisms. 
Induction of metabolic enzymes and efflux transporters is one of the mechanisms 
associated with poor response to chemotherapy. Smoking has been shown to induce 
CYP3A4 in in vitro studies.  Hamilton et al reported that erlotinib, a drug primarily 
metabolized by CYP3A4 has a 2.8 fold lower systemic exposure in smokers than 
nonsmokers. Opiates are hallucinogens that are abused by many adults and teenagers 
around the world. Morphine is one of the most potent alkaloids of opium and is one of the 
main reasons for the extremely addictive nature of opiates. Morphine is used to treat 
moderate to severe pain and is a substrate of p-glycoprotein. Chronic exposure has been 
shown to enhance p-glycoprotein expression in rat brain. This upregulation of p-gp 
enhanced morphine efflux from the rat brain. Brain p-gp expression increased by 2 fold 
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in morphine treated rats when compared to saline treated rats.  HIV protease inhibitors 
are generally administered for prolonged time periods to eliminate the viral sanctuaries in 
brain, lungs and lymph glands.  Since nicotine and morphine has been abused for longer 
time periods, there is a need to evaluate the long term effect of nicotine and morphine on 
the induction of the efflux transporters and CYP3A4 proteins and functional activity.  
 
Introduction 
              Drug-drug interactions involving efflux transporters and drug metabolizing 
enzymes are divided in two main categories: inhibition resulting in enhanced toxicity and 
induction resulting in loss of efficacy. P-glycoprotein, product of human MDR1 gene, 
transports numerous neutral and cationic compounds and effluxes them out of the cell 
using ATP94. P-glycoprotein is expressed in normal tissues such as gastrointestinal track, 
liver, kidney, testis and brain, where it prevents the accumulation of toxic substances 
(Figure-3.1). P-gp is overexpressed in cancer cells and confers resistance to a variety of 
compounds such as vinca alkaloids, anthracyclines, colchicines and paclitaxel95. CYP3A4 
is involved in the metabolism of diverse chemotherapeutic compounds and accounts for 
approximately 30% of hepatic CYP and more than 70% of intestinal activity. CYP3A4 is 
the main contributor to presystemic elimination following oral administration. Previous 
in vitro studies suggests that 40-50% of the drugs administered in humans are 
metabolized by CYP3A496.  
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            Both p-gp and CYP3A4 act synergistically to increase presystemic metabolism. 
P-glycoprotein mediated efflux increases the intestinal residence time and efflux of the 
metabolites of the drug results in more extensive metabolism by CYP3A4. In addition, 
overlapping specificity of the two proteins, similarities in gene regulation and tissue 
distribution of p-gp and CYP3A4 and the close spatial proximity of CYP3A4 to the 
apical membrane where p-gp is expressed supports the synergistic relationship between 
CYP3A4 and p-glycoprotein97. CYP3A4 mediated metabolism and p-gp mediated efflux 
are the two main barriers to drug absorption at intestine. Due to the overlapping and 
broad substrate specificity of p-glycoprotein and CYP3A4, drug-drug interactions involve 
both the enzyme and transport systems. Both CYP3A4 and p-gp are present at higher 
concentration in the villus enterocytes of small intestine, the primary site of absorption of 
orally administered drugs98.  
               Many clinically significant drug-drug interactions have been reported involving 
their role. Inhibition of p-gp and CYP3A4 can cause an elevation in plasma/tissue drug 
concentrations can lead to toxicity, especially for drugs possessing narrow therapeutic 
index. Induction of p-gp and CYP3A4 can lead to subtherapeutic concentrations of the 
affected drug leading to therapeutic failure99. Many drugs such as Rifampicin, 
phenobarbital, carbamazepine are known to cause induction of CYP450 isoforms 
resulting in decrease of systemic exposure of coadministered drugs metabolized by 
CYP450. Herbal agents such as St. John’s wort enhance hepatic and intestinal CYP3A4 
activity through the activation of pregnane-x-receptor100. PXR is a member of nuclear 
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receptor superfamily of ligand regulated transcription factors. PXR is a key xenobiotic 
receptor that regulates the expression of genes encoding drug metabolizing enzymes and 
transporters. Studies have demonstrated that PXR is widely expressed in cancerous 
tissues as well as normal tissues such as liver and small intestine. PXR mediated 
induction of efflux transporters leading to decrease in the intracellular accumulation of p-
gp substrates101. Enhanced p-gp expression has been associated with poor treatment 
response in various malignancies102.  
 
Figure 3.1  Efflux transporters localization across various tissues 
Morphine is the opioid of choice for the treatment of moderate to severe pain, and is a 
substrate of p-glycoprotein. Morphine is one of the most potent alkaloids of opium and is 
one of the main reasons for the extremely addictive nature of opiates. After heroin, 
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morphine has the greatest dependence liability of the narcotic analgesics in common use 
and for heroin to be effective, it must be converted in the body to morphine103. Previous 
studies have demonstrated that brain p-gp levels were increased significantly in morphine 
tolerant rats. However, short term exposure of morphine did not result in any significant 
differences in p-gp expression and activity104. Nicotine is a major constituent of tobacco 
and it has been recently demonstrated that nicotine is an activator of PXR which regulates 
the gene expression of both p-gp and CYP3A4105.  
           HIV protease inhibitors are known to have low oral bioavailability predominantly 
due to extensive hepatic metabolism as well as intestinal metabolism. Clinically 
important drug interaction has been proved between HIV protease inhibitors and herbal 
drugs such as St. John’s wort and grape fruit juice106. Study of mechanism of drug-drug 
interactions between morphine and nicotine and HIV protease inhibitors can improve 
therapeutic strategies and individualization of therapy in drugs abusing HIV population.  
Studies using in vitro model cell lines are useful in identifying potential interactions and 
possibly permitting extrapolation of in vitro findings to in vivo scenarios.  Opioid drugs 
are generally converted to morphine. Morphine is commonly used to study the effects in 
vitro and in vivo. Several drugs of abuse like morphine, nicotine, cocaine, alcohol are 
now identified as critical factors affecting drug disposition and drug interactions. 
Cigarette smoking is the greatest risk factor for lung cancer and cigarette smoking 
exposes the airways to at least 4000 chemicals107. Tobacco smoke may cause significant 
pharmacokinetic or pharmacodynamic interactions and plasma concentration–time 
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profiles108. According to American cancer society, cigarette smoking accounts for at least 
30% of all cancer deaths. Nicotine is a poisonous alkaloid found in substantial amounts in 
all forms of tobacco and is one of the heavily used addictive drug in US109.  Nicotine is a 
weak base with a pKa of 8.0 with most of its absorption occurring in unionized state. 
After absorption, Nicotine distributes rapidly throughout various tissues, including brain, 
liver, kidney and intestine. About 1-2 mg of nicotine is absorbed systemically during 
smoking110.  
             In view of this, there is a need to study the long term effects of these drugs. 
Furthermore, their role in the induction of other efflux transporters such as BCRP has to 
be elucidated. Our current study explores the long term effects of morphine and nicotine 
by utilizing model cell lines LS180. Selective induction of in vitro CYP3A4 and p-gp 
expression by morphine and nicotine was observed in LS180 cells. Our results 
demonstrate that morphine and nicotine differentially can induce p-gp and CYP3A4. The 
results can offer mechanistic explanation in chronic nicotine and morphine users. 
 
Materials and Methods 
Cell Culture and Treatment Conditions 
               LS180 cells (human colon adenocarcinoma cell line) and Caco-2 cells (human 
colonic carcinoma cell line), HepG-2 were used for the studies. Cell lines were 
maintained according to previously published protocols from our lab. Cells were cultured 
in Dubelcco’s Modified Eagle Medium supplemented with 10% heat inactivated fetal 
 bovine serum, MEM non
(100 µg/ml) and streptomycin (100 µg/ml). For the treatment, confluent cells were 
exposed to nicotine (2.5 µ
µM) for 72 hours. Fresh medium containing the above mentioned concentrations of 
nicotine, morphine and rifampicin were added to the culture medium every day for the 
length of the treatment time. Final concentration of DMSO did not exceed 0.5% for 
rifampicin treated cells. 
morphine and experiments were designed as shown in figure
 
  
Figure 3.2  Experimental design to study the expression and functional activity of 
efflux transporters 
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-essential amino acids, HEPES, sodium bicarbonate, penicillin 
M, 10 µM), morphine (3 µM and 10 µM) and rifampicin (2
Cells were treated with selected concentrations of nicotine and 
-3.2. 
5 
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Real Time PCR Studies 
              RNA was extracted from the control and nicotine treated lung tissues using 
Trizol reagent (Invitrogen). All samples were normalized to 1 µg of total RNA. 1 µg of 
total RNA was mixed with 1.25 µl oligo dT primer at 70ºc for 10 minutes and then 
reverse transcribed to cDNA using MMLV-reverse transcriptase enzyme. Real time PCR 
was according to a standard protocol published by Roche. Real time PCR primers were 
designed using oligo perfect designer. All the primers were designed such that the 
amplicons generated were between 100-200 bp long to increase the efficiency of 
simultaneous amplification of target and reference genes. Briefly, the PCR mixture has a 
volume of 20 µl. SYBR green kit from Roche has 2X concentration of PCR master mix 
and PCR grade water. To this master mix, 250 nM each of forward and reverse primers of 
gene of interest were added.  5 µg/µl cDNA sample was added to this master mix to 
prepare 20 µl of PCR sample. The samples were then carefully centrifuged at 3000 g for 
2 minutes. Samples were analyzed and fluorescence was quantified. 
Table-2   RT-PCR primers for MDR1 and CYP3A4 
Gene Oligonucleotide  sequence (5΄-3΄) Location 
Product 
Size 
(bps) 
MDR1 Forward        CAGAGGGGATGGTCAGTGTT 1758 
109 
Reverse        CGTGGTGGCAAACAATACAG 1867 
CYP3A4 Forward        ACCGTGACCCAAAGTACTGG 1309 
118 
 Reverse        GTTTCTGGGTCCACTTCCAA 1427 
GAPDH Forward        CAATGACCCCTTCATTGACC 201 
105 
 Reverse        GACAAGCTTCCCGTTCTCAG 306 
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Western Blot 
            Whole cell protein was extracted with reagent containing 3.2 mM Na2HPO4, 0.5 
mM KH2PO4, 1.3 mM KCl, 135 mM NaCl, 1% Triton X - 100 and protease inhibitor 
cocktail at pH 7.4. Confluent cells were washed thrice with PBS and harvested using a 
cell scraper in 5 mL of PBS. The cell suspension was centrifuged at 1500 rpm for 10 
minutes and the pellet was resuspended in freshly prepared lysis buffer for 15 minutes on 
ice.  The extracted protein was then obtained by centrifugation and stored at -80oC. 
Protein content was determined using Bradford method. Polyacrylamide gel 
electrophoresis (PAGE) was run with 25 and 50 µg of each protein at 120 V, 250 mAmp. 
Transfer was carried out on polyvinylidene fluoride (PVDF) membrane at 25 V for 1 h 30 
min, on ice. Immediately after transfer, the blot was blocked for 3 hours in freshly 
prepared blocking buffer (2.5 % non-fat dry milk and 0.25 % bovine serum albumin 
prepared in TBST pH-8). After a light wash for 10 sec, the blots were exposed to primary 
antibodies overnight (dilution - 1:500 for p-glycoprotein and CYP3A4). Blots were then 
exposed for 2 hours to secondary antibodies obtained from Santa Cruz biotechnology (1: 
5000). The blots were finally washed three times with TBST and developed using 
SuperSignal West Pico chemiluminescence substrate. The blots were exposed for 30 sec 
after which the image was taken in Gel Doc Imager. 
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Uptake Studies 
              After treatment with morphine and nicotine, cells were rinsed three times with 
DPBS (pH 7.4, 129 mM NaCl, 2.5mM KCl, 7.4mM Na2HP04, 1.3 mM KH2PO4, 1 mM 
CaCl2, 0.7 mM MgSO4 and 5.3 mM glucose) and equilibrated for 15 minutes with the 
buffer. [3H]lopinavir (0.5 µCi/ml), [3H]abacavir (0.5 µCi/ml) and [14C]erythromycin (0.1 
µCi/ml) were used as model substrates for MDR1, BCRP and MRP2 to determine the 
cellular accumulation. Uptake studies were performed by incubating the cells with fixed 
amount of 0.5 µCi/ml of the radioactive substrate for 30 minutes. Following incubation, 
the reaction was stopped by addition of ice cold stop solution (210 mM KCl, 2 mM 
HEPES; pH 7.4). After three washings with stop solution, cells were lysed by keeping 
them overnight in 1 ml of 0.1% Triton-X solution in 0.3% NaOH. Following overnight 
incubation, 500 µl of the cell lysate from each well was transferred to scintillation vials 
containing 5 ml of scintillation cocktail (Fisher Scientific, Fair lawn, NJ). Samples were 
analyzed by liquid scintillation counter (Beckman instruments Inc., CA, USA) and uptake 
was normalized to the protein content in each well. Amount of protein in the cell lysate 
was measured by the Bio-Rad protein estimation kit with bovine serum albumin as 
standard.  
VIVID Assay 
             Functional activity of metabolizing enzyme (CYP3A4) in HepG2 cells was 
assayed using VIVID™ CYP3A4 Red Substrate (Invitrogen), which was prepared as a 
20mM stock solution in acetonitrile. Briefly, HepG2 cells were plated in 96 wells and 
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treated as described earlier. After 5 days of treatment, the cells were lysed and CYP3A4 
activity assay was assayed according to the manufacturer’s protocol. The rate of 
fluorescent metabolite production from the metabolism of a Vivid® CYP450 substrate 
was monitored kinetically at 37°C over a period of 30 minutes using a 96 well plate 
reader (SpectraFluor Plus, Maennedorf, Switzerland) at an excitation wavelength of 530 
nm and an emission wavelength of 585 nm. The readings were normalized to protein 
count as mentioned earlier. 
Calcein-AM Assay 
            Culture medium was first removed from the 96 well plates and washed with 
DPBS buffer at pH-7.4. Cells were treated with morphine, nicotine and rifampicin for 7 
days. Following treatment, intracellular accumulation of calcein-AM was determined for 
the remaining studies. Cells were incubated with varying calcein-AM 1 µM for 15 
minutes.  After 15 min incubation, reaction was arrested with stop solution (210 mM KCl 
and 2 mM HEPES; pH 7.4) and lysed with 1 ml of lysis buffer (0.1% Triton-X solution in 
0.3% NaOH). Amount of intracellular calcein was measured with a fluorescence 
spectrophotometer. Excitation and emission filters were set at 370 and 450nm and the 
intracellular mean fluorescence was normalized to protein content.  
 
Cytotoxicity Studies 
           LS180 cells and Caco-2 cells were exposed to nicotine, morphine for seven days. 
Following the treatment, cells were incubated with MTT [3-(4,5-dimethylthiazol-2-yl)-
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2,5-diphenyl tetrazolium bromide] reagent according to the previously published 
protocol. 
 
Data Analysis 
           Data for the uptake studies was analyzed by student’s t-test. The criteria of 
significance between the means (± standard deviation) were p < 0.05. Each experiment 
was performed in triplicate.  
 
Results and Discussion 
            Expression of efflux transporters and metabolizing enzymes play a significant role 
in modulation of chemotherapeutic drugs across various cellular barriers. Inhibition and 
induction of these transporters have been reported to be one of the major cause of 
variability in intracellular drug accumulation. An altered expression of p-glycoprotein 
and CYP3A4 can have important clinical outcomes111. Inhibition can result in enhanced 
plasma concentrations leading to toxicity whereas induction can result in reduced plasma 
concentrations leading to therapeutic failure112.  While most of the studies have 
investigated the in vitro p-glycoprotein and CYP3A4 inhibition studies, fewer studies 
have focused on their induction mechanisms. In this study, the effect of chronic exposure 
of morphine and nicotine on the expression and activity of p-glycoprotein, MRP2, BCRP 
and CYP3A4 in vitro was investigated. LS180, a human colon adenocarcinoma cell line 
was employed as a model cell line for in vitro studies. Previously, it was shown that 
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prolonged exposure to morphine can enhance the expression of p-glycoprotein in rat 
brain. Induction of p-glycoprotein led to reduced accumulation of morphine to rat 
brain113. However, the ability of morphine to induce MRP2 and BCRP was not 
investigated. Nicotine’s effects on p-gp and CYP3A4 are also of clinical importance 
because it is a known activator of PXR. Eventhough, nicotine has been shown to induce 
CYP2D6, its effects on CYP3A4 and other efflux transporters MRP2, BCRP were never 
studied.   
 
Quantification of MDR1 mRNA Expression in LS180 Cells 
             
 
Figure 3.3 Quantification of MDR1 mRNA in LS180 cells (+ indicates 2.5 µM and 
++ 10 µM for nicotine; + indicates 3 µM and ++ 10 µM for morphine; + indicates 
25 µM for rifampicin)   (* indicates significant difference compared to control; 
p<0.05, n = 3 ± S.D) 
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Expression of MDR1 was detected after treating LS180 and Caco-2 cells for 72 hours and 
10 days respectively. For functional uptake studies, LS180 and Caco-2 cells were treated 
for 7 and 15 days respectively. Following treatment, RNA was extracted and subjected to 
reverse transcriptase and gene expression was analyzed by real time PCR. Differential 
induction in MDR1 mRNA levels was observed following chronic morphine and 
nicotine.  
 
Induction of MDR1 mRNA in Caco-2 Cells 
 
Figure 3.4  Quantification of MDR1 mRNA in Caco-2 cells (+ indicates 2.5 µM and 
++ 10 µM for nicotine; + indicates 3 µM and ++ 10 µM for morphine; + indicates 
25 µM for rifampicin)   (* indicates significant difference compared to control; 
p<0.05, n = 3 ± S.D) 
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Chronic treatment with nicotine for 72 hours did not alter MDR1 mRNA levels 
compared to control. Morphine (3 µM and 10 µM) enhanced MDR1 mRNA by 1.8 and 
3.2 fold respectively whereas rifampicin (25 µM), a positive inducer enhanced the MDR1 
mRNA by 20.4 fold. GAPDH was used as a house keeping gene. Figure-3.3 shows the 
quantification of MDR1 mRNA following treatment.   Since Caco-2 cells were treated for 
10 days for gene expression studies, RT-PCR was also performed in Caco-2 cells to 
quantify MDR1 mRNA levels. Following treatment, morphine (3 µM) enhanced MDR1 
mRNA levels by 5.12 fold and nicotine (2.5 µM) increased MDR1 mRNA levels 
significantly by 3.95 fold respectively (figure-3.4).    
 
Western Blot Analysis of P-gp in Caco-2 Cells 
  Western blot analysis indicated significant p-gp protein induction following 
treatment with morphine and nicotine. Morphine and nicotine successfully induced p-gp 
protein levels in Caco-2 cells (figure-3.5). 
 
 
Figure 3.5   Immunoblot for the expression of CYP3A4 in Caco-2 cells. Total protein 
lysates probed for the efflux transporter P-gp. Growth medium (control: lane 1) or 3 
µM morphine (lane 2), 2.5 µM nicotine (lane 3). Each lane contains 20 µg of protein 
lysate. 
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Uptake Study to Determine P-gp Functional Activity 
               To determine the functional activity of the efflux transporters, uptake studies 
were performed to measure the intracellular accumulation. LS180 and Caco-2 cells were 
exposed to morphine and nicotine for seven days and 15 days respectively for uptake 
studies. Following treatment, cells were incubated with radioactive labeled substrates 
[3H] lopinavir, [3H] digoxin for 30 minutes.  
 
Figure 3.6  Uptake of radioactive substrates in LS180 cells Intracellular 
accumulation of [3H] lopinavir, [14C] erythromycin and [3H] abacavir was measured 
by incubating the  LS180 cells for 30 min in the absence (control) or presence of 
morphine(3 µM) and nicotine (2.5 µM). Values are means of quadruplicates with 
standard deviation indicated by error bars. Asterisk (*) indicates a significant (P< 
0.05) difference from the mean control value using Student’s one-tailed t-test. 
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After 30 minutes, intracellular accumulation of radioactive substrates was decreased 
significantly when compared to control. Short term incubation of these radioactive 
substrates (lopinavir, erythromycin and abacavir) with morphine and nicotine had no 
effect on their accumulation of radioactive substrates in LS180 cells (figure-3.6). This 
data indicated that the reduction in intracellular accumulation was due to the altered 
induction of efflux transporters rather than inhibition.  
 
Digoxin and Lopinavir Uptake in LS180 Cells 
 
Figure 3.7 Digoxin uptake in LS180 cells Intracellular accumulation of [3H] digoxin 
was measured by incubating LS180 cells for 30 min without treatment (control) or 
treatment with morphine (3 µM) and nicotine (2.5 µM) for seven days. (+ indicates 
2.5 µM and ++ 10 µM for nicotine; + indicates 3 µM and ++ 10 µM for morphine) 
Values are means of triplets with standard deviation indicated by error bars. 
Asterisk (*) indicates a significant (P< 0.05) difference from the mean control value 
using Student’s one-tailed t-test. 
 Figure 3.8 Lopinavir uptake
Intracellular accumulation of [
cells for 30 min without treatment (control) or treatment with nicotine (2.5 µM) and 
nicotine (10 µM) for seven days. 
deviation indicated by error bars. Asterisk (*) indicates a significant (
difference from the mean control value using Student’s one
Figure 3.9  Lopinavir uptake
Intracellular accumulation of [
cells for 30 min without treatment (control) or treatment with morphine (3 µM) and 
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 following nicotine treatment in LS180 cells
3H] lopinavir was measured by incubating LS180 
Values are means of triplets with standard 
-tailed 
 
 following morphine treatment in LS180 cells
3H] lopinavir was measured by incubating LS180 
morphine (10 µM) for seven days. 
Nicotine 2.5 µM Nicotine 10 µM
Morphine 3 µM Morphine 10 µM
*
*
 
 
P< 0.05) 
t-test. 
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As shown in figure (3.7, 3.8, 3.9), morphine reduced the intracellular accumulation of 
[3H]lopinavir and [3H]Digoxin significantly suggesting the induction of p-gp functional 
activity. However, nicotine had no significant effect on intracellular accumulation of p-gp 
substrates when compared to control.  
 
Uptake Studies in Caco-2 Cells 
               In another set of studies, Caco-2 cells exposed to morphine and nicotine also 
showed a significant reduction in intracellular accumulation of [3H] lopinavir and [3H] 
saquinavir (figure-3.10 and 3.11). A known potent inducer of efflux transporters, 
rifampicin 25 µM was used as a positive control to study its effects on the uptake of 
radioactive substrates.   
 
Figure 3.10   Lopinavir uptake following morphine and nicotine treatment in Caco-2 
cells Intracellular accumulation of [3H] lopinavir was measured by incubating 
LS180 cells for 30 min without treatment (control) or treatment with nicotine (2.5 
µM) and morphine (3 µM) for 15 days. Values are means of triplets with standard 
deviation indicated by error bars. Asterisk (*) indicates a significant (P< 0.05) 
difference from the mean control value using Student’s one-tailed t-test.  
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Figure 3.11  Saquinavir uptake following morphine and nicotine treatment in Caco-
2 cells Intracellular accumulation of [3H] saquinavir was measured by incubating 
LS180 cells for 30 min without treatment (control) or treatment with morphine (3 
µM) and nicotine (2.5 µM) and for 15 days.  
These results confirmed that the observed decline in the uptake of radioactive substrates 
following chronic morphine and nicotine treatment was due to the altered expression of 
p-glycoprotein. Since Caco-2 cells were exposed to longer time than LS180 cells, 
expression and functional activity mediated by MDR1 was much higher than in Caco-2 
cells when compared to LS180 cells.     
Calcein-AM Assay in LS180 Cells 
                To determine the functional significance of this increase in P-gp expression, the 
cellular uptake of P-gp substrate calcein-AM was evaluated at the selected concentration 
ranges. A significant decrease in calcein accumulation by LS180 cells was observed in 
the cells exposed to morphine and nicotine confirming the reduced functional activity of 
P-gp. Figure 3.12 demonstrated the decrease in P-gp activity following LS180 cells 
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treatment with morphine and nicotine. This data clearly established that exposure to 
morphine and nicotine contributes to increased efflux activity. 
 
 
 
Figure 3.12: Calcein-AM assay study in LS180 cells Intracellular accumulation of 
calcein was measured by incubating  LS180 cells with calcein-AM for 60 min 
without treatment (control) or treatment with morphine (1 µM, 3 µM and 10 µM) 
and nicotine (1 µM , 2.5 µM and 10 µM) for seven days. Values are means of 6 
samples with standard deviation indicated by error bars.  
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CYP3A4 Expression and Functional Activity  
             We also evaluated the effect of morphine and nicotine on CYP3A4 mRNA 
expression in LS180 cells. Morphine and nicotine had no significant effect on CYP3A4 
mRNA levels in LS180 cells when compared to control (figure-3.13). This may be due to 
lower basal CYP3A4 levels in LS180 cells. Also, 72 hour treatment duration with 
morphine and nicotine was not significant enough to induce CYP3A4 mRNA levels in 
LS180 cells.  
 
Figure 3.13   Quantification of CYP3A4 mRNA in LS180 cells (+ indicates 2.5 µM 
and ++ 10 µM for nicotine; + indicates 3 µM and ++ 10 µM for morphine; + 
indicates 25 µM for rifampicin)   (* indicates significant difference compared to 
control; (** indicates significant difference compared to control; ** p<0.01, 
n = 3 ± S.D)  
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CYP3A4 Induction Studies 
            Morphine and nicotine significantly enhanced CYP3A4 protein expression when 
compared to control (figure-3.14). Morphine and nicotine displayed a higher increase in 
CYP3A4 protein levels than CYP3A4 mRNA transcript levels.  
 
 
 
Figure 3.14  Quantification of CYP3A4 protein in LS180 cells. Total protein lysates 
probed for CYP3A4 Growth medium (control: lane 1), 2.5 µM nicotine, N1 (lane 2) 
10 µM nicotine, N2 (lane 3) 3 µM morphine, M1 (lane 4), 10 µM morphine, M2 (lane 
3). Each lane contains 20 µg of protein lysate. 
Vivid CYP3A4 Assay in HepG2 Cells 
               After studying the gene expression, CYP3A4 enzyme activity was measured by 
performing VIVID CYP3A4 assay kit containing blue fluorescent substrate following 
treatment of HepG2 cells with morphine and nicotine. Following these treatments, 
CYP3A4 activity was measured as the rate of fluorescent metabolite production over the 
course of reaction with VIVID assay. Induction was calculated as the activity observed 
after treatment with inducer relative to treatment with 0.1 % DMSO (control).  
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Figure 3.15   Vivid CYP3A4 assay in HepG2 cells Enhanced activity of CYP3A4 
HepG2 in the presence of morphine and nicotine. HepG2 cells were treated with 
morphine (3 µM), nicotine (2.5 µM) and rifampicin (50 µM). 
Asterisk * indicates significant difference relative to control; p<0.05, n = 8 ± S.D. 
 
 
Figure 3.15 clearly demonstrates the higher CYP3A4 activity in HepG2 cells exposed to 
morphine and nicotine. Nicotine produced almost three fold higher CYP3A4 activity 
when compared to control. This study confirmed the ability of morphine and nicotine to 
induce CYP3A4 protein levels.   
Cell Viability Studies 
              Cell viability studies were performed to determine the cytotoxic potential of 
morphine and nicotine in LS180 and Caco-2 cells. Cells were treated with morphine (3 
µM, 10 µM), nicotine (2.5 µM, 10 µM), DMSO (0.1%), rifampicin (25 µM). LS180 cells 
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exposed to morphine and nicotine for 7 days did not show any significant cytotoxicity 
(figure-3.16 A).  
A) 
 
Figure 3.16   Cell viability studies A) Viability of LS180 cells following 
treatment with morphine (3, 10 µM), nicotine (2.5, 10 µM) and rifampicin (25 µM). 
 
In a different study, treatment of Caco-2 cells with morphine (3 µM), and nicotine (2.5 
µM), did not produce any significant toxicity (figure-3.16 B). However, rifampicin (25 
µM) reduced the cell viability by 84% following treatment.  
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Figure 3.16   Cell viability studies B) Viability of Caco-2 cells following treatment 
with morphine (3 µM), nicotine (2.5 µM) and rifampicin (25 µM). (* indicates 
significant difference relative to control; p<0.05, n = 8 ± S.D) 
Induction of MRP2 Expression in LS180 Cells 
            To determine the expression of MRP2 mRNA following treatment, RT-PCR was 
performed to quantify mRNA levels. Morphine (3 µM and 10 µM) increased MRP2 
mRNA by 1.5 and 3.35 fold respectively (figure 3.17).  
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Figure 3.17   Quantification of MRP2 mRNA in LS180 cells (+ indicates 2.5 µM and 
++ indicates 10 µM for nicotine; + indicate 3 µM and ++ indicates 10 µM for 
morphine; + indicates 25 µM for rifampicin)   (* indicates significant difference 
compared to control; p<0.05, (** indicates significant difference compared to 
control p<0.01, n = 3 ± S.D) 
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Figure 3.18: Quantification of [14C] Erythromycin accumulation following nicotine 
and morphine treatment in LS180 cells. A) Intracellular accumulation of [14C] 
Erythromycin was measured by incubating LS180 cells for 30 min without 
treatment (control) or treatment with nicotine (2.5 µM and 10 µM) for seven days. 
B) treatment with morphine (3 µM and 10 µM) for seven days. Values are means of 
triplets with standard deviation indicated by error bars. Asterisk (*) indicates a 
significant (P< 0.05) difference from the mean control value using Student’s one-
tailed t-test. 
Radioactive erythromycin was used as positive control to quantify MRP2 mediated efflux 
in LS180 cells. Exposure to morphine and nicotine for 72 hours reduced the intracellular 
accumulation of radioactive erythromycin when compared to control (figure-3.18 A, B).   
ABCG2 mRNA Induction Studies in LS180 Cells 
             ABCG2 mRNA levels enhanced by 4 and 3.43 fold by nicotine (2.5 µM and 10 
µM) respectively whereas morphine (3 µM and 10 µM) increased ABCG2 mRNA levels 
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by 4.33 and 4.88 fold respectively (figure-3.19).  Interestingly, nicotine showed much 
higher induction of ABCG2 mRNA than MDR1 and MRP2 expression in LS180 cells. 
 
Figure 3.19   Quantification of ABCG2 mRNA in LS180 cells (+ indicates 2.5 µM 
and ++ indicates 10 µM for nicotine; + indicate 3 µM and ++ indicates 10 µM for 
morphine; + indicates 25 µM for rifampicin)   (* indicates significant difference 
compared to control; p<0.05, (** indicates significant difference compared to 
control; p<0.01, n = 3 ± S.D)  
BCRP Protein Induction in LS180 Cells 
             We investigated whether ABCG2 mRNA activation was translated into protein 
induction in this study. Western blot analysis showed that compared to control, there was 
an increase in BCRP protein expression following exposure to morphine (3 µM), nicotine 
(2.5 µM) and rifampicin (25 µM) (figure-3.20).  
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Figure 3.20  Immunoblot for the expression of BCRP in LS180 cells. Total protein 
lysates probed for the efflux transporter BCRP. Growth medium (control: lane 1), 3 
µM morphine (lane 2), 2.5 µM nicotine (lane 3) and 25 µM Rifampicin. Each lane 
contains 20 µg of protein lysate. 
Abacavir Uptake in LS180 cells Following Treatment 
We investigated whether augmented BCRP efflux function was observed in 
LS180 cells exposed to nicotine and morphine. Uptake of [3H] abacavir was reduced 
significantly in LS180 cells exposed to nicotine and morphine when compared to control 
(figure-3.21 A, B).  
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B) 
 
Figure 3.21: Quantification of [3H] abacavir accumulation following nicotine 
and morphine treatment in LS180 cells. A) Intracellular accumulation of 
[3H] abacavir was measured by incubating LS180 cells for 30 min without 
treatment (control) or treatment with nicotine (2.5 µM and 10 µM) for seven 
days. B) treatment with morphine (3 µM and 10 µM) for seven days. Values 
are means of triplets with standard deviation indicated by error bars. 
Asterisk (*) indicates a significant (P< 0.05) difference from the mean control 
value using Student’s one-tailed t-test. 
 
 
Transport Studies 
 
Apical to basolateral transport studies were performed after treating LS180 cells with 
morphine and nicotine (10 µM). [3H] lopinavir and [3H] abacavir transport were used as 
model substrates. Results from transport studies also support the data from uptake 
studies. Transport of abacavir reduced significantly when compared to lopinavir 
following chronic exposure to morphine and nicotine (figure 3.22 and figure 3.23)   
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Figure 3.22: A-B transport of [3H] lopinavir following nicotine and morphine 
treatment in LS180 cells. 
 
 
 
 
Figure 3.23: A-B transport of [3H] abacavir following nicotine and morphine 
treatment in LS180 cells. 
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   Potential Model to Study
             LS180 cells are an intestinal colon carcinoma cells that express characteristics of 
small intestine. Therefore, this c
transporters and metabolizing enzymes. Although, LS180 cells constitutively express p
gp, PXR and CYP3A4, but in our studies morphine and nicotine had no significant 
induction on CYP3A4 mRNA levels. 
vinblastine (100 nM) displayed enhanced MDR1 and CYP3A4 expression and activity. 
Therefore, we treated LS180 cells with vinblastine and performed real time PCR to 
quantify MDR1 and CYP3A4 mRNA expression. Our s
and lopinavir enhanced MDR1 and CYP3A4 mRNA levels when compared to control 
(figure-3.22). This vinblastine selected LS180 cells can be a potential model to study 
MDR1 and CYP3A4 induction mechanisms.  
Figure 3.24  Quantification of 
indicates 10 µM for nicotine, 10 µM for lopinavir
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 Induction Based Drug-Drug Interactions 
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Conclusions 
          In summary, our results confirmed that chronic morphine and nicotine exposure of 
LS180 cells can differentially induce the expression and activity of P-gp, MRP2, BCRP 
and CYP3A4.  Even though, the induction of expression and functional activity by 
morphine and nicotine was not high enough to produce this interaction in in vitro 
scenarios, the possibility of these drug-drug interaction could occur as it should be noted 
that these drugs are abused for years and the intracellular concentrations of HIV protease 
inhibitors can be declined drastically leading to therapeutic failure.  These observations 
illustrate the in vitro mechanistic effect of drug-drug interactions between morphine and 
nicotine and HIV protease inhibitors.  Clinical studies often fail to assess the mechanisms 
behind the therapeutic failure of HIV patients. These studies may explain the variable 
complex and plasma concentrations and treatment outcomes of HIV infected patients as 
well as HIV infected patients addicted to drugs of abuse. Morphine and nicotine effects 
on MRP2 and BCRP expression and functional activity are also of clinical significance as 
there is limited information available on their interactions. Previous studies have 
provided evidence that HIV protease inhibitors are substrates for p–glycoprotein and 
CYP3A4 and thereby co-administered drugs that are substrates, inhibitors and inducers 
modulate the expression of p-gp and CY3A4 resulting in the alteration of  their 
intracellular accumulation. This reduced accumulation may potentially promote the 
emergence of mutant viruses at the sanctuary sites.  
 
 Table-3   Induction of efflux transporters by morphine and nicotine
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CHAPTER-4 
INFLUX TRANSPORTERS IN LUNGS: EXPRESSION OF FOLIC ACID 
CARRIERS IN HUMAN BRONCHIAL EPITHELIAL CELL LINE, CALU-3  
Rationale 
Drugs can be delivered either via the pulmonary route by intratracheal instillation to treat 
systemic diseases or via inhalation of aerosolized drugs to treat local respiratory 
diseases114. Mechanisms of drug delivery across bronchial and alveolar epithelium have 
been investigated over the years, but little is known about the mechanism underlying the 
pathways regulating the transport of peptide and folate related compounds across 
pulmonary epithelium. Also, role of these transporters in the biopharmaceutics of the 
inhaled drugs is progressively being recognized. For example, several anti-infectious 
such as penicillin and cephalosporin antibiotics active against bacterial infections are 
substrates for PEPT1/PEPT2 transporters. Also, folate substrates such as methotrexate are 
substrates for folic acid transporters. Presence of these transporters across pulmonary 
epithelium can potentially affect the absorption and distribution of the drugs which are 
substrates for these influx transporters. Moreover, peptide and folate prodrugs can 
influence the kinetics of the pulmonary drugs. Therefore, the aim of this specific aim is to 
determine the expression and functional activity of folic acid receptor/transporter and 
peptide transporters in Calu-3, human bronchial epithelial cell line, Calu-3, in vitro. 
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Introduction 
             Folic acid transport is an important physiological process that maintains the folic 
acid homeostasis in the body. Folates are members of vitamin B9 family. Folate and folic 
acid are two forms of the same water soluble vitamin which occurs naturally in food such 
as leafy vegetables and fruits. Folic acid plays an essential role in cell growth and 
differentiation, red blood cell production, protein metabolism and several other 
biochemical processes115. Folates are essential cofactors for one carbon donor substrates 
involved in nucleotide and methionine synthesis116. Several therapeutic drugs such as 
methotrexate, 5-fluorouracil, raltitrexed, pemetrexed have been targeted to interfere with 
folate pathways and folate dependent enzymes for the treatment of cancerous as well as 
non-cancerous tissues117. Clinical studies have revealed that plasma levels of folate and 
genetic polymorphisms in folate dependent enzymes are often associated with increased 
risk of cancer, heart disease, peripheral vascular disease and dementia118. Previous studies 
also demonstrated the protective role of dietary folate on lung carcinogenesis119. 
Mammalian cells cannot synthesize folic acid de novo, and therefore rely on exogenous 
nutritional sources for their metabolic requirements. Since folates are highly hydrophilic 
bivalent anions, they can only minimally navigate through the biological membranes by 
simple diffusion process. Therefore, their internalization through mammalian cell 
membranes must occur by means of a carrier mediated process. Structurally and 
functionally diverse carriers transport folic acid across epithelia and into systemic tissues. 
Three major classes of folate transport mechanisms are reported for cellular entry of 
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folates i.e., folate receptor (α, β and γ), folate transporter (reduced folate carrier 1) and 
proton-coupled folate transporter (PCFT). RFC1, a member of major facilitator 
superfamily encodes for a sequence of 60 kDa protein whereas folate receptors belong to 
a family of 32-36 kDa membrane anchored glycoproteins 120. RFC1 is a low affinity, high 
capacity bidirectional transporter involved in folate uptake by many tissues like intestine, 
pancreas and liver. Folate receptor alpha (FR-α) is a high affinity, low capacity system 
that has been utilized to target polymer based systems and drugs to tumors that 
overexpress high levels of this receptor 121. RFC1 has higher affinity for reduced folate 
forms like methotrexate whereas folate receptor has higher affinity for folic acid than 
reduced folate forms. Recently, Qiu et al identified a human proton coupled, high affinity 
folate transporter (PCFT) in HeLa, HepG2 and Caco-2 cells122. PCFT is a 50 kDa 
electrogenic, proton coupled high affinity transporter that   mediates the translocation of 
folates across the membranes. Prodrugs targeting specific high affinity carriers have been 
utilized for improving systemic concentrations of drugs with low oral bioavailability. 
Targeting specific carriers in the airway epithelium may improve drug uptake and 
delivery across pulmonary epithelial cells. Folic acid conjugation has been used 
successfully to deliver several macromolecules due to its small size, high affinity, 
selectivity, availability and lack of immunogenicity. Folate conjugation has also been 
employed for tumor targeted gene delivery in lungs. Folate targeted liposomes, 
nanoparticles and dendrimers have several advantages for tissue specific targeting since 
folic acid has higher affinity coupled with overexpression of folate carriers in certain 
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forms of tumors 123. Pulmonary delivery of various therapeutic substances following local 
and systemic administrations is of high clinical significance and has widely been 
investigated for a variety of respiratory diseases, such as asthma, pulmonary hypotension, 
chronic obstructive pulmonary disease and cystic fibrosis124.  
 
   Figure- 4.1 Airway and alveolar epithelium          
               Inhalation route has been successfully indicated as a potential alternative to 
parenteral administration of proteins and peptidomimetic drugs due to advantages like 
large surface area of lung (~70-140 m2), relatively permeable mucosa, and escape from 
first pass metabolism, lower enzymatic activity and higher vascularization. Bronchial 
epithelium is a major barrier to transport of macromolecules as it restricts paracellular 
diffusion (figure 4.1). However, little information is known about the mechanism of folic 
acid transport across the bronchial epithelium. Therefore, the objective of this study was 
to investigate the presence of folate transporters in human bronchial epithelial cell line, 
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Calu-3 and to functionally characterize the role of folic acid transporters across human 
bronchial epithelium. Several cell lines (A549, Calu-3, BEAS-2B and 16 HBE14o-), 
primary cultures (hAEpC) and isolated lung perfusion models have been established to 
investigate pulmonary drug transport mechanisms. Calu-3 cell line, derived from 
bronchial epithelium, has been employed as a model for the air way epithelium in a 
number of drug transport and metabolism studies. These cells form polarized monolayers 
with tight junctions producing high TEER values. They also produce several cell 
adhesion proteins (ZO-1 and E-cadherin) and mucosal secretions 125. In vitro-in vivo 
studies indicated a good correlation (0.94) between permeability characteristics of Calu-3 
cells with that of rat lung 126. Therefore, Calu-3 cell line was selected as a model to 
investigate the transport of folic acid across respiratory epithelium. 
   
Materials and Methods 
Cell Culture  
            Calu-3 cell line, an airway epithelium derived cell line from human lung 
carcinoma was procured from ATCC. Calu-3 cells between passages 15-40 were 
employed for all the studies. Cells were cultured in DMEM-F12 (Dubelcco’s Minimum 
Essential Medium) supplemented with 10% heat inactivated fetal bovine serum, non-
essential amino acids (NEAA), HEPES, sodium bicarbonate, penicillin (100units/ml) and 
streptomycin (100 µg/ml) were purchased from Sigma Chemical Co. Cells were 
maintained at 37oC, in a humidified atmosphere of 5% CO2 and 90% relative humidity. 
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The medium was replaced every alternate day. Cells were subcultured with 0.25% trypsin 
containing 0.537 mM EDTA and plated onto 12 well plates.  
 
RT-PCR 
            Isolation of total RNA from cells was carried out using Trizol-LS® reagent 
according to manufacturer’s instructions. In brief, Calu-3 cells grown in a culture flask 
(75 cm2 growth area) were lysed by adding 800 µl of Trizol reagent. The lysate was then 
transferred to Eppendorf tubes. RNA was extracted by the phenol–CHCl3–isopropranolol 
method and dissolved in 50 µl of RNase–DNase-free water. RNA was mixed with 1.25 µl 
of oligo dT15 primer to prepare the first strand cDNA. After denaturation, it was reverse 
transcribed to cDNA using 1 µl (10 units) of Moloney Murine Leukemia Virus Reverse 
Transcriptase per reaction mixture. After the first strand cDNA synthesis, 1 µl of cDNA 
was used for PCR.  The primers were designed by. amplification of cDNA was 
performed using primers mentioned in Table-4. Briefly, the PCR mixture has a final 
volume of 50 µl and contains the relevant template cDNA, 250 nM each of forward and 
reverse primers for the gene of interest, 1X Mg free PCR buffer (Promega), 3.75 mM 
MgCl2, 0.025U Taq Polymerase, and 200 µM dNTPs, The polymerase chain reaction 
conditions of denaturation at 94°C for 2 min, followed by 30 cycles of 94°C for 30 sec, 
50°C for 30 sec and 72°C for 45 sec with a final extension at 72°C for 10 min were used 
for the studies. PCR products were separated by 2% agarose gel in tris-acetate-EDTA 
 buffer along with 100 bp ladder.
imaging. 
 
Table-4   PCR primers for folic acid transporters and receptor
. 
 
Western Blot           
           Whole cell protein was extracted 
mM KH2PO4, 1.3 mM KCl, 135 mM NaCl, 1% Triton X 
cocktail at pH 7.4. Confluent cells were washed thrice with PBS and harvested using a 
cell scraper in 5 mL of PBS. The cell suspension 
minutes and the pellet was resuspended in freshly prepared lysis buffer for 15 minutes on 
ice.  The extracted protein was then obtained by centrifugation and stored at 
used. Protein content was determined usi
electrophoresis (PAGE) was run with 25 and 50 µ
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 Bands were visualized by ChemiImager 8900 digital 
 
with reagent containing 3.2 mM Na2HPO4, 0.5 
- 100 and protease inhibitor 
was centrifuged at 1500 rpm for 10 
ng Bradford method. Polyacrylamide gel 
g of each protein at 120 V, 250 mAmp. 
 
-80oC, until 
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Transfer was carried out on polyvinylidene fluoride (PVDF) membrane at 25 V for 1 h 30 
min, on ice. Immediately after transfer, the blot was blocked for 3 hours in freshly 
prepared blocking buffer (2.5 % non-fat dry milk and 0.25 % bovine serum albumin 
prepared in TBST pH-8). After a light wash for 10 sec, the blots were exposed to primary 
antibodies overnight (dilution - 1:500 for PCFT, 1:400 for FR-alpha, 1:300 for RFC)  
Antibodies for PCFT and RFC were gifts from Professor Sylvia B. Smith whereas goat 
polyclonal antibody for FR-alpha (SC-16386) was obtained from Santa Cruz 
Biotechnology. The blots were then exposed for 2 hours to secondary antibodies obtained 
from Santa Cruz Biotechnology (1: 5000 for PCFT, 1: 5000 for FR-alpha, 1: 5000 for 
RFC). The blots were finally washed three times with TBST and developed using 
SuperSignal West Pico chemiluminescence substrate. The blots were exposed for 30 sec 
after which the image was taken in Gel Doc Imager. 
 
Uptake Studies 
               Uptake studies were conducted in 12 well plates with confluent cell monolayers. 
At 11-14 days post seeding, the cells reached confluency. Then, the medium was 
removed and cells were rinsed three times, 5 min each with 2 ml of DPBS (pH 5.0, 129 
mM  NaCl, 2.5mM KCl, 7.4mM Na2HP04, 1.3 mM KH2PO4, 1 mM CaCl2, 0.7 mM 
MgSO4 and 5.3 mM glucose) and equilibrated for 30 minutes with the buffer. All the 
uptake experiments were carried out by incubating a fixed amount of [3H]folic acid 
(0.5µCi/ml, concentration-20 nM) at 370C with or without other test compounds. At the 
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end, the test solutions were removed and uptake process was stopped by adding ice cold 
stop solution (210 mM KCl and 2 mM HEPES; pH 7.4). After three washings with stop 
solution, cells were lysed overnight in 1 ml of 0.1% Triton-X solution in 0.3% NaOH. 
Following overnight lysis, 500 µl cell lysate from each well was transferred to 
scintillation vials containing 5 ml of scintillation cocktail. Samples were analyzed by 
liquid scintillation counter and the uptake values were normalized to the protein content 
in each well. Amount of protein present in the cell lysate was measured by Bradford 
reagent using bovine serum albumin as standard.  
 
Time dependency: Time dependent uptake of [3H]folic acid was performed at different 
time periods from 1 to 60 minutes. Cells were incubated with [3H]folic acid at different 
time periods and the reaction was terminated by adding stop solution. In addition, time 
dependent uptake of [3H]folic acid was carried out in presence of 10 µM methotrexate. 
 
pH dependency: The effect of variation of incubation buffer pH was examined on the 
folic acid uptake. Incubation buffer was adjusted to 5.0, 6.0, 7.4 and 8.0 for pH 
dependence studies.  
 
Concentration dependency: Stock solutions (5mg/ml) of unlabeled folic acid were 
prepared in DMSO (less than 2%v/v in water). Different concentrations (0.01 µM-25 
µM) of folic acid were then prepared by diluting adequate quantities of stock solutions 
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with DPBS buffer. Then fixed amount of [3H]folic acid (0.5 µCi/ml) was spiked to the 
different dilutions and uptake at different concentrations was carried out according to  
previously described procedures. 
 
Sodium and chloride dependency:  To determine the effect of Na+ and Cl- ions, uptake of 
folic acid was performed with sodium free and chloride free DPBS buffer. Equimolar 
quantities of Choline chloride and dibasic potassium phosphate (K2HPO4) were used as 
replacement for sodium chloride (NaCl) and dibasic sodium phosphate (Na2HPO4) 
respectively to obtain sodium free buffer. Chloride free buffer was prepared by 
substituting with equimolar quantities of monobasic sodium phosphate (NaH2PO4), 
monobasic potassium phosphate (KH2PO4) and calcium acetate in place of sodium 
chloride (NaCl), potassium chloride (KCl) and calcium chloride (CaCl2).  
 
Temperature dependency:  To determine whether uptake was temperature dependent, 
cells were incubated with [3H]folic acid  for 15 minutes at 37°C, room temperature and 
4°C.  
 
Energy dependency: To investigate whether the transport of folic acid is energy 
dependent, 1 mM ouabain (Na+ /K+ -ATPase inhibitor) and 1 mM sodium azide 
(metabolic inhibitor) were added. All the inhibitors were preincubated for one hour prior 
to a study and uptake was conducted for 15 minutes.  
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Substrate specificity: To examine specificity, uptake of [3H]folic acid was examined in 
the presence of 10 µM structurally related compounds (unlabeled folic acid and 
methotrexate). Uptake was also studied in the presence of 1 mM unlabeled vitamins 
(ascorbic acid, thiamine and nicotinic acid). These experiments were conducted to 
elucidate the structural properties of the substrates required for interaction with the carrier 
system. 
 
Effect of membrane transport inhibitors and receptor inhibitors: Uptake of [3H]folic acid 
was carried out to investigate the presence of a receptor mediated process or an anion 
exchange process on the apical side. Prior to the initiation of an uptake experiment, the 
cells were incubated for one hour with anion transport inhibitors; probenecid (1 mM) and 
amiloride (1 mM) as well as receptor mediated endocytosis inhibitors; colchicine (10 
µM) and cytochalasin D (10 µM). After one hour treatment, uptake of [3H]folic acid was 
carried out for 15 minutes. 
 
 Effect of sulfasalazine and thiamine pyrophosphate on folic acid uptake: PCFT and RFC 
mediated uptake of folic acid uptake was determined in Calu-3 cells following 
preincubation with sulfasalazine (10 µM, 50 µM and 100 µM) and thiamine 
pyrophosphate (100 µM and 500 µM) for 1 hour. Folic acid uptake was determined for 
15 minutes. 
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Statistical Analysis 
            All results were expressed as mean ± standard deviation. Statistical analysis 
between two groups of data was carried out using Student’s t-test. A difference between 
mean values was considered significant if the P-value was less than 0.05.  
 
Results and Discussion 
            Carrier mediated transport of  folic acid is ubiquitously present in mammalian 
cells since folic acid is required for cellular proliferation, cell survival and tissue 
regeneration. Pulmonary route for local and systemic diseases has been successfully 
employed to deliver several macromolecules. Pulmonary residence time, the drawback 
associated with pulmonary drug delivery may be controlled by selective drug targeting 
with carriers. Studies involving the mechanism and functional aspects of folate uptake in 
the respiratory tract may be useful for selective drug targeting through prodrugs.                     
The present study investigates the presence of a carrier mediated system involved 
in the regulation of folic acid transport across Calu-3, human bronchial epithelium cell 
line. Calu-3 cell line has been validated as a metabolic and transport model to study the 
mechanisms of respiratory drug delivery at respiratory epithelium.  Calu-3 cell line has 
been employed as a model based on its tight junctions, permeability of low molecular 
weight lipophilic compounds, expression of efflux pumps and influx transporters and 
metabolic enzymes. Calu-3 cell line is a well-established model and previous studies in 
our laboratory have demonstrated transport of insulin and HIV protease inhibitors across 
 Calu-3 cells127. Therefore, we selected 
the presence of a carrier mediated system for folic acid and to delineate the mechanism 
involved in the uptake of folic acid by bronchial epithelium. 
 
RT-PCR for Folic acid C
                 Resulting cDNA was used as a template for PCR reaction. Primers 
FR-alpha, RFC-1 and PCFT were designed for PCR. Amplified PCR products obtained 
were separated by 2% agarose gel electrophoresis and bands were visualized.  As shown 
in Figure 4.2, bands were detected at approximately and 729, 407, and 625 bp f
GAPDH, FR-alpha and PCFT respectively.
 
Figure 4.2   PCR for folic acid transporters and receptor
(lane 1), GAPDH (lane 2), RFC (lane 4), FR
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Western Blot Analysis 
             To further characterize the folate transporters, Western blot analysis were carried 
out to determine the protein expression of PCFT, RFC and FR-alpha. Studies revealed 
specific bands at 65 KDa and 37 KDa for PCFT and FR-alpha respectively (Figure 4.3). 
RFC was not expressed in the protein homogenate extracted from Calu-3 cells. β-actin 
was used as a positive control. These results correlated well with the PCR results.  
 
Figure 4.3  Western blot for PCFT and FR-α 
 
Time Dependent Study of [3H] Folic Acid 
               Uptake of [3H] folic acid by Calu-3 cells was examined as a function of time. 
Uptake was found to be linear for up to 60 minutes as depicted in Figure 4.4. Therefore, 
all the subsequent uptake studies were conducted over 15 minutes. At 15 min, the uptake 
of [3H]folic acid was 0.3 pmole/mg protein. 
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Figure 4.4  Time dependent study of [3H]folic acid  
Uptake of [3H]Folic acid at Different  pH 
            Uptake of [3H]folic acid significantly decreased in Calu-3 cells when the pH of 
incubation buffer was increased from 5.00 to 8.00. Uptake was higher at pH-5 (0.030 
±0.002 pmol/min/mg) relative to other pH values (Figure 4.5). At pH-7.4, uptake rate of 
[3H]folic acid was found to be 0.0086 ±0.0006 pmol/min/mg. Therefore, all further 
studies were conducted at pH-5.00. This effect may indicate the presence of an inwardly 
directed proton gradient being involved in the uptake of folic acid. Folate transporter 
which is effective at low pH was also found in human rat intestinal brush border 
membrane vesicles 128 and human retinal pigmental cells (ARPE-19) 129. 
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Figure 4.5   pH dependent study of [3H]folic acid 
 
Concentration Dependent Study of [3H]Folic Acid 
To determine the saturation kinetics, uptake of [3H]folic acid was examined in the 
presence of various concentrations (0.01 µM-10 µM) of unlabeled folic acid. Unlabeled 
folic acid significantly inhibited the uptake of [3H]folic acid. Uptake data was fitted to a 
modified Michaelis-Menton equation and kinetic parameters for folic acid uptake were 
determined by non-linear regression analysis of the data. Apparent KM and Vmax were 
calculated to be 0.33 ± 0.03µM and 22.04 ± 0.0009 pmol/min/mg protein respectively 
(figure-4.6). This data is further supported by substrate specific inhibition of folic acid in 
the presence of folate analogues like methotrexate. Previous studies demonstrated a Km 
value of 1.4 µM for a carrier mediated transport system for folic acid across human 
colonic epithelial cell line NCM460  130.  
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Figure 4.6   Kinetic parameters for folic acid uptake 
Effect of transmembrane ion gradient on the uptake of folic acid was investigated by 
repeating the experiments in Na and Cl free medium. The absence of Na+ and Cl- in the 
incubation buffer had no significant effect on the uptake of folic acid (data not shown). 
 
Energy Dependent Uptake of Folic Acid 
To investigate whether transport of folic acid is energy dependent, 1 mM ouabain 
(Na+ /K+ -ATPase inhibitor) and 1 mM sodium azide (metabolic inhibitor) were added. 
All inhibitors were preincubated for one hour prior to a study and uptake was conducted 
over 15 minutes.  
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Figure 4.7   Energy dependent study of [
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Substrate Specificity Study
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Figure 4.9  Temperature dependent study of 
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              In a separate experiment, possible role of receptor mediated endocytosis was 
investigated by treating Calu
significantly reduced the uptake of folic acid.
 
Figure 4.10  Uptake of [
endocytosis inhibitor. Asterisk (*) 
the mean control value using Student’s one
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            To examine any possible involvement of an anion exchange mechanism for folate 
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mM  caused significant inhibition (46.6% and 76.04% respectively) in folic acid uptake 
as illustrated in Figure 4.11. 
  
 
Figure 4.11  Uptake of [3H]folic acid in presence of SITS and DIDS, anion transport 
inhibitors.  Asterisk (*) indicates a significant (P< 0.05) difference from the mean 
control value using Student’s one-tailed t-test. 
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Uptake of Folic Acid in Presence of Sulfasalazine and Thiamine Pyrophosphate 
            Sulfasalazine and thiamine pyrophosphate were proven to be specific inhibitors of 
PCFT and RFC respectively. To determine the inhibitory effect of sulfasalazine and 
thiamine pyrophosphate on PCFT mediated uptake, Calu-3 cells were incubated with 
increasing concentrations of sulfasalazine for one hour. Uptake of [3H]folic acid was 
performed for 15 minutes at 37°C. Uptake was found to decrease significantly by 89.7%, 
63.4% and 22.9% for 10 µM, 50 µM and 100 µM respectively as shown in figure 4.12. 
These results further indicate the presence of PCFT mediated uptake in Calu-3 cells.  
 
A) 
 
 
0
20
40
60
80
100
120
Control SZ 10 µM SZ 50 µm SZ 100 µM
Up
ta
ke
 
(%
 
o
f c
o
n
tr
o
l)
*
*
90 
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Figure 4.12  Uptake of [3H]folic acid in presence of A) Sulfasalazine and B) 
Thiamine pyrophosphate  
 
Functional Activity of Peptide Transporter 
Several peptidomimetic antibiotics are frequently used for local drug therapy in 
pulmonary infections. Glycylsarcosine, radioactive substrate of peptide transporter was 
used as a model substrate to study the functional activity in Calu-3 cells. Uptake of [14C] 
Gly-sar was performed at acidic pH 5.00. Uptake of [14C] Gly-sar was inhibited by 1 mM 
cold Gly-sar, cefradine and cefadroxil indicating the presence of peptide transporter at the 
apical membrane of human bronchial epithelial cells, Calu-3 (figure-4.13). Studies by 
Gronberg et al also indicated the presence of peptide transporter in lungs.   
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Figure 4.13    Uptake of [3H]Gly-sar in presence of peptide substrates 
 
Effect of Nicotine on Peptide and Folic acid Transporter Activity 
             We wanted to investigate the effect of nicotine on activity of  influx transporters  
peptide and folic acid transporter. Calu-3 cells were treated with nicotine for 11 days and 
uptake of [3H]Gly-sar and [3H]folic acid was determined.  As shown in figure- 4.14 and 
4.15, uptake of radioactive Gly-sar and folic acid was reduced significantly after 
exposing Calu-3 cells to nicotine. This data indicated that chronic nicotine treatment 
inhibited the activity of influx transporter. This data conclude that there can be 
involvement of  inhibition of activity of influx transporters in cells treated with nicotine.    
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standard deviation indicated by error bars. 
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Calu-3 cells 
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Conclusions 
              In conclusion our results confirmed the molecular identity of PCFT and FR-
alpha in human bronchial epithelial cell line, Calu-3. Also, we functionally characterized 
the transport of folic acid mediated by PCFT across Calu-3, human bronchial epithelial 
cell line. Our findings may offer new strategies to treat chronic pulmonary diseases by 
designing folate linked compounds. Data from this study also revealed the effect of 
nicotine on the activity of influx transporters, peptide and folic acid. Reduced Gly-sar and 
folic acid uptake indicate that chronic nicotine exposure through cigarette smoking can 
modulate the uptake of inhaled drugs in lungs. More experiments should be designed to 
study the effect of chronic cigarette smoking on the expression and activity of influx 
transporters in lungs.  
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CHAPTER-5 
TO STUDY THE ROLE OF EFFLUX TRANSPORTERS IN HUMAN 
BRONCHIAL EPITHELIAL CELL LINE, CALU-3 
Rationale 
           Efflux transporter proteins have the potential to critically alter the systemic 
exposure and bioavailability of the drug substrates and therefore influence the modulation 
the absorption and disposition of the drugs. Efflux transporters have the ability to 
recognize and transport a diverse range of endogenous substrates, xenobiotics and 
pharmaceutically relevant drugs. Many efflux proteins such as p-glycoprotein, MRP2, 
BCRP and lung resistance proteins mediate the multidrug resistance of the 
chemotherapeutic agents. Several inhaled drugs are substrates of efflux transporters and 
hence their localization and activity influence the delivery of these drugs to the site of 
their action (figure-5.1). Current studies aim to investigate the localization and activity of 
these efflux transporters in lungs. Since, local concentration of the drugs is the most 
important factor for the eradication of bacteria and viruses, role of efflux transporters 
across bronchial and alveolar epithelium needs to be thoroughly investigated. Calu-3, a 
human bronchial epithelial cell line has been employed as an in vitro model for efflux 
studies. Therefore, overall aim of this chapter was to investigate the molecular presence 
and activity of the efflux transporters. Specifically p-glycoprotein and MRP mediated 
activity of the model p-gp and MRP substrates were examined. This research will give 
insights in the preclinical development of pulmonary drugs.  
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Introduction 
               Pulmonary route has been successfully utilized as an alternative route for the 
systemic delivery of chemotherapeutic agents both for local delivery and systemic 
delivery. Several efforts have been made to deliver these agents for systemic 
administration as well as local conditions. In particular, inhaled insulin has been explored 
extensively for the treatment of diabetes mellitus. Lungs have a comparatively larger 
surface area (70 m2) than other mucosal tissues such as nasal, buccal, rectal and vaginal 
routes. In addition, the lower thickness of the alveolar epithelium (0.1-0.5 µm), rich 
vascularization, rapid absorption followed by rapid onset of action, lower enzymatic 
degradation and escape of first pass  liver metabolism makes it as an attractive route for 
delivery of proteins. About 90% of the absorptive surface area of the lungs is due to the 
alveoli. Alveolar epithelial with tight intercellular junctions form a major barrier for the 
absorption of high molecular weight substances. Small molecular weight compounds less 
than 40 kDa are absorbed by paracellular transport whereas larger molecular weight 
agents are absorbed by transcytosis. Previous studies have shown that proteins that have a 
molecular weight up to approximately 30 kDa have bioavailability between 20-50%. The 
lower bioavailability is due to the degradation of proteins by the proteolytic enzymes 
present in the lungs. Penetration enhancers such as chelators, surfactants, bile salts and 
fatty acids are often used to enhance the pulmonary absorption. These penetration 
enhancers might alter the integrity of the mucosal membrane, inhibit the proteolytic 
activity and affect the membrane lipids and proteins. Inhaled particles get filtered and 
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subsequently deposited on the airways due to progressive branching of the 
tracheobronchial tree. These particles are then cleared by two mechanisms: mucociliary 
clearance and alveolar macrophages. Mucociliary escalator results from the upward 
movement of the mucus secretions (produced by the goblet cells and mucus secreting 
glands) by the cilia that beat at about 1000 to 1500 per minute. Mucus gets cleared at a 
rate of 0.5 to 20 mm/minute towards the trachea and then swallowed into the 
gastrointestinal track. Inhaled toxic particles get phagocytosized by alveolar macrophages 
present in the alveoli. Also, these macrophages secrete several inflammatory mediators 
such as interleukins, leukotrienes, granulocyte colony-stimulating factors and proteases 
that degrade the proteins. However, to elicit proper systemic effect, the major challenge is 
to develop formulations that can deliver the aerosol particles to the deep lung. Particle 
size and velocity are the two main factors that govern the deposition of particles to the 
deep lung. For efficient deposition, the particles should have mass median aerodynamic 
diameter between 1 and 3 µm. For targeted deposition to the alveolar region, the mass 
median aerodynamic diameter should not be more than 3 µm. Aerosol particles with 
diameter greater than 6 µm gets deposited in the oropharynx. Three major types of 
devices have been used to deliver aerosol particles to the lungs:  metered dose inhalers, 
nebulizers and dry powder inhalers. To control the release of drug from the administered 
dose, proteins are encapsulated in particulate delivery systems such as liposomes, 
microparticles, nanoparticles and dendrimers. PEG, PLGA, PLA and chitosan are most 
commonly used for encapsulating the proteins. These polymers improve the physical as 
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well as chemical stability and protect the protein molecules from loss of confirmation. 
Exubera was the first approved inhaled formulation of insulin developed by Pfizer for the 
treatment of hyperglycemia in type 1 and 2 diabetic patients. However, this product was 
discontinued due to its potential to develop side effects and its inability to deliver precise 
insulin doses. AIR Insulin System (Eli Lilly), AERX Insulin Diabetes Management 
System (Novo Nordisk), Technosphere Insulin System (Mannkind) are some of the 
delivery devices that are currently in phase-ІІІ clinical trials for the delivery of inhaled 
insulin.  
             Efflux transporters play an important role in preventing accumulation of 
potentially toxic xenobiotics in the lung 131. Gumbleton et al described the spatial 
expression of the several efflux transporters in lungs132 (figure-5.1). 
 
Figure 5.1   Localization of efflux transporters in lungs 
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Efflux pumps along with mucociliary clearance, alveolar macrophages and bactericidal 
surfactants act as a protective barrier in the lungs. Recent studies have shown that 
majority of the BCRP substrates were basic lipophilic amines which readily accumulate 
in lung tissue. P-glycoprotein has also been shown to play a role in the pulmonary 
accumulation of fluoroquinolones133.  
           Also, efflux transporters such as P-gp and MRPs have been attributed to drug 
resistance in lung cancers134. BCRP is also involved in efflux of various 
chemotherapeutic agents employed in lung cancer which include mitoxantrone, 
doxorubicin, topotecan135 and gefitinib136. Elevated mRNA levels have been correlated 
with resistance to these anticancer agents in lung cancer. BCRP expression in lungs might 
play a role in the disposition of drugs in cancer chemotherapy. Therefore, our objective is 
to identify and characterize the expression of BCRP in human bronchial epithelial cells. 
            Various cell lines were utilized to investigate the expression and modulation of 
BCRP. Calu-3 cell line, derived from bronchial epithelium, has been employed as a 
model for the air way epithelium in a number of drug transport and metabolism studies. 
Several advantages of Calu-3 cell line in comparison to other models of the airway 
epithelium, such as tracheal epithelial sheets or primary tracheal cell cultures have been 
reported. Calu-3 cells form polarized monolayers with high tight junctions producing 
high TEER values. These cells express in vivo features of the airway epithelium (cilia, 
mucus production), several transport and metabolic systems relevant to drug absorption. 
These cells also produce several cell adhesion proteins (ZO-1 and E-cadherin) and 
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generate mucosal secretions. In vitro-In vivo studies indicated good correlation (0.94) 
between permeability properties of Calu-3 cells with the rate of drug absorption from the 
rat lung (figure-5.2). Previous investigations established the functional activity of various 
efflux proteins belonging to ABC transporter super family such as MDR1 137 and MRP-1  
in Calu-3 cells. Therefore, Calu-3 cell line has been selected as a model cell line to 
investigate the BCRP expression and to estimate its functional activity.   
 
Figure 5.2   In vitro and In vivo correlation of permeability of Calu-3 cells  
 
Materials and Methods 
Materials 
                  [3H]Ritonavir (3 Ci/mmol) was purchased from Moravek biochemicals (Brea, 
CA, USA). Cells between passages 20-40 were used for all the studies.  
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Cell Culture  
           Cells were cultured in DMEM-F12 medium supplemented with 10%  heat 
inactivated fetal bovine serum, MEM non-essential amino acids, HEPES, sodium 
bicarbonate, penicillin (100 µg/ml) and streptomycin (100 µg/ml). Cells were maintained 
at 37oC, in a humidified atmosphere of 5% CO2 and 90% relative humidity. Medium was 
replaced every alternate day until 5 days and subsequently every day until 11 days. Cells 
were subcultured by trypsinization with 0.25% trypsin containing 0.537 mM EDTA. 
 Uptake Studies 
           At 11-13 days post seeding, cells were rinsed three times with DPBS (pH 7.4, 129 
mM NaCl, 2.5mM KCl, 7.4mM Na2HP04, 1.3 mM KH2PO4, 1 mM CaCl2, 0.7 mM 
MgSO4 and 5.3 mM glucose) and equilibrated for 15 minutes with the buffer. 
[3H]Ritonavir was used as a model substrate to characterize functional activity. Uptake 
studies were performed by incubating a fixed amount of 0.5 µCi/ml of [3H]ritonavir alone 
and in the presence of P-gp and MRP inhibitors at 370C. Following incubation, the 
reaction was stopped by addition of ice cold stop solution (210 mM KCl, 2 mM HEPES; 
pH 7.4). After three washings with stop solution, cells were lysed by keeping them 
overnight in 1 ml of 0.1% Triton-X solution in 0.3% NaOH. Following overnight 
incubation, 500 µl of the cell lysate from each well was transferred to scintillation vials 
containing 5 ml of scintillation cocktail. Samples were analyzed by liquid scintillation 
counter and uptake was normalized to the protein content in each well. Amount of protein 
in the cell lysate was measured by the Bio-Rad protein estimation kit with bovine serum 
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albumin as standard. Functional activity was assessed by studying the uptake of [3H]-
ritonavir in presence of various inhibitors. 
 
 Statistical Analysis 
          All results were expressed as mean ± standard deviation. All the experiments were 
done in triplicate. Statistical analysis between two groups of data was carried out with a 
student’s t-test. A difference between mean values was considered significant at the P-
value less than 0.05.  
 
 Discussion 
             Cellular drug resistance conferred by multidrug resistance (MDR) proteins is a 
major challenge in cancer chemotherapy. Tumor cells can acquire resistance to a single 
drug or to a class of cytotoxic drugs or to a broad spectrum of structurally and 
functionally diverse chemotherapeutic agents. The cellular mechanisms of MDR involve 
reduced drug uptake, activation of DNA repair and detoxification process, defective 
apoptotic signals 138 and most commonly, active transport of drugs out of the cells 
mediated by efflux pumps 139. P-glycoprotein (P-gp/ABCB1) has been widely 
investigated as a MDR transporter for many years.  
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MDR1 Inhibition Studies 
                To study the existence of p-glycoprotein mediated efflux in Calu-3 cells, uptake 
of ritonavir, a well-known p-gp substrate was examined. Intracellular accumulation of 
[3H]-Ritonavir in the presence and absence of p-gp efflux inhibitors ketoconazole (25 
µM, 50 µM and 100 µM) and quinidine (75 µM) was depicted in figure 5.3.  
 
Figure 5.3  Uptake of radioactive ritonavir in presence of ketoconazole and 
quinidine 
 
A 2.6 fold increase of intracellular ritonavir uptake was noticed in presence of 50 µM 
ketoconazole when compared to control. However, there was an increase of 2.83 fold 
uptake of ritonavir in presence of 75 µM quinidine, a known p-gp inhibitor (figure-5.3).  
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Ketoconazole inhibited the efflux mediated by p-gp in a concentration dependent manner. 
This data indicate the role of p-gp mediated efflux of HIV protease inhibitor ritonavir in 
Calu-3 cells.  
MRP Expression in Calu-3 Cells 
               Cellular RNA was isolated and RT-PCR was performed to determine MRP2 
expression in Calu-3 cells. Figure 5.4 demonstrates MRP2 mRNA expression and a clear 
band was noticed at 412 bp.     
 
 
 
 
 
 
 
Figure 5.4  RT-PCR results for MRP2 expression in Calu-3 cells. Molecular weight 
ladder (lane 1) and MRP2 (lane 2) 
 
Uptake Studies 
                MK571, a leukotriene D4 antagonist is a specific inhibitor of MRP mediated 
transport active against MRP2, MRP1 and MRP3. Uptake of ritonavir was performed in 
the presence of various concentrations of MK-571. As demonstrated in figure-5.5, MK-
571 inhibited the MRP2 mediated efflux of ritonavir in concentration dependent manner. 
                 1                  2 
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Uptake of ritonavir was increased significantly by 5.26 fold with 75 µM MK571 which 
confirmed the presence of MRP2 mediated transport of ritonavir in Calu-3 cells.  
 
Figure 5.5  Uptake of [3H] ritonavir in presence of MK-571.  Intracellular 
accumulation of [3H] ritonavir was measured by incubating Calu-3 cells for 30 min 
in the absence (control) or presence of  MK571, MRP inhibitor. Values are means of 
quadruplicates with standard deviation indicated by error bars. Asterisk (*) 
indicates a significant (P< 0.05) difference from the mean control value using 
Student’s one-tailed t-test. 
Basolateral Uptake of [3H]Ritonavir in Calu-3 Cells 
            To determine the MRP functional activity on the basolateral side, basolateral 
uptake studies were performed in presence of MRP inhibitors, MK-571 and 
sulfinpyrazone. In these experiments, [3H]-Ritonavir was added to the basolateral 
chamber of a transwell and accumulation of radioactive ritonavir in the apical chamber 
was analyzed.  
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Figure 5.6  Basolateral uptake of [3H] ritonavir in presence of MK571 (50 µM) and 
sulfinpyrazone (1 mM).  Intracellular accumulation of [3H] ritonavir was measured 
by incubating Calu-3 cells  in the absence (control) and presence of  MK571, MRP 
inhibitor and sulfinpyrazone on the basolateral side. Values are means of 
quadruplicates with standard deviation indicated by error bars. Asterisk (*) 
indicates a significant (P< 0.05) difference from the mean control value using 
Student’s one-tailed t-test. 
As shown in figure-5.6, MK-571 inhibited the MRP1 mediated efflux by 1.5 fold 
resulting in enhanced intracellular accumulation of ritonavir. Addition of 1 mM 
sulfinpyrazone (MRP inhibitor) to the basolateral chamber caused inhibition of ritonavir 
uptake by 1.45 fold when compared to control.   
 
106 
 
Transport Studies of [3H]Ritonavir 
The amount of [3H]ritonavir transported after 180 minutes across the Calu-3 monolayers 
was higher in the basolateral-apical direction than apical-basolateral direction. Also, the 
amount of [3H]ritonavir transported enhanced in the presence of MK571, a known MRP 
inhibitor. These results are also supported by the uptake results that show the MRP2 
mediated transport of ritonavir.  
 
 
Figure 5.7  A-B and B-A transport of [3H]-Ritonavir in Calu-3 cells 
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Figure 5.8   A-B and B-A transport of [3H]-ritonavir in presence of MK-571 (50 µM) 
 
Conclusions 
              This study demonstrates the presence and functional activity of MRP2 and 
MRP1 in human bronchial epithelial cell line, Calu-3. Also, this study clearly indicates 
that ritonavir is actively effluxed by p-glycoprotein and MRP2 and there is possibility of 
drug-drug interaction in vivo due to the localization of these efflux transporters.  
However, role of MRP2 on the absorption of inhaled drugs needs to be investigated.    
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CHAPTER-6 
TO CHARACTERIZE THE MOLECULAR AND FUNCTIONAL ACTIVITY OF 
BREAST CANCER RESISTANCE PROTEIN IN HUMAN BRONCHIAL 
EPITHELIAL CELLS, CALU-3  
Rationale 
            Breast cancer resistance protein (BCRP), a 72 kDa protein belongs to the 
subfamily G of the human ATP binding cassette transporter superfamily. Overexpression 
of BCRP was found to play a major role in the development of resistance against various 
chemotherapeutic agents. BCRP plays an important role in absorption, distribution and 
elimination of several therapeutic agents. BCRP expression and functional activity across 
human bronchial epithelium and its impact on pulmonary drug accumulation has not been 
established. Efflux transporters are believed to play an important role in preventing 
accumulation of potentially toxic xenobiotics in the lung 131. Efflux pumps along with 
mucociliary clearance, alveolar macrophages and bacteriocidal surfactants act as a 
protective barrier in the lungs. Recent studies have shown that majority of the BCRP 
substrates were basic lipophilic amines which readily accumulate in lung tissue. P-
glycoprotein has also been shown to play a moderate role in the pulmonary accumulation 
of amine drugs. Also, efflux transporters such as P-gp and MRPs have been attributed to 
drug resistance in lung cancers. BCRP is also involved in efflux of various 
chemotherapeutic agents employed in lung cancer which include mitoxantrone, 
doxorubicin, topotecan 135 and gefitinib 136. Elevated mRNA levels have been correlated 
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with resistance to these anticancer agents in lung cancer. BCRP expression in lungs might 
play a role in the disposition of drugs in cancer chemotherapy. Therefore, our objective is 
to identify and characterize the expression of BCRP in human bronchial epithelial cells. 
 
Introduction 
              Breast cancer resistance protein (BCRP) was initially identified in a breast 
cancer derived cell line that showed drug resistance even in the presence of verapamil (a 
potent P-gp inhibitor) 140. This protein was termed BCRP as it was first isolated from a 
human MCF-7 breast cancer cell line in an attempt to elucidate non-P-glycoprotein 
mechanisms of drug resistance. This efflux pump was also identified in a mitoxantrone-
resistant human colon carcinoma cell line S1-M1–80 and hence gained the name MXR 48.  
BCRP/MXR is the second member of subfamily G of ATP-binding cassette 
(ABC) transporter superfamily. It is also referred to as ABCP (P stands for placenta), to 
indicate high levels of expression in placental tissue. BCRP, MXR and ABCP are 
homologous proteins differing only in one or two amino acid sequence. BCRP 
structurally diverges from the other prominent ABC transporters. BCRP is termed as half 
transporter having only six transmembrane helices and only one nucleotide binding 
domain. With the help of low resolution crystallography, it has been shown that 
functional BCRP has a homodimeric structure 50, 141.   
BCRP is a high efficiency efflux pump with broad substrate specificity 142. BCRP 
expression is maximum in placenta and significantly high in the intestine and liver. 
110 
 
BCRP expression in colon, brain, lungs, ovary and testis has also been reported 143. 
Various categories of drugs such as tyrosine kinase inhibitors, antivirals, HMG-CoA 
reductase inhibitors, carcinogens and flavonoids have been reported to be either 
substrates and/or inhibitors of this transporter system 142. Studies with ABCG2 knockout 
mice have revealed the physiological significance of this efflux transporter across barriers 
such as blood-brain, blood-testis and blood-fetal barriers 144. It plays a protective role 
across these barriers by active efflux of xenobiotics, pollutants, chemicals and toxins. 
Various cell lines were utilized to investigate the expression and modulation of 
BCRP 143, 145. Calu-3 cell line, derived from bronchial epithelium, has been employed as a 
model for the air way epithelium in a number of drug transport and metabolism studies 
125, 146
. Several advantages of Calu-3 cell line in comparison to other models of the airway 
epithelium, such as tracheal epithelial sheets or primary tracheal cell cultures have been 
reported. Calu-3 cells form polarized monolayers with high tight junctions producing 
high TEER values 126. These cells express in vivo features of the airway epithelium (cilia, 
mucus production), several transport and metabolic systems relevant to drug absorption. 
These cells also produce several cell adhesion proteins (ZO-1 and E-cadherin) and 
generate mucosal secretions 125. In vitro-In vivo studies indicated good correlation (0.94) 
between permeability properties of Calu-3 cells with the rate of drug absorption from the 
rat lung 126. Previous investigations established the functional activity of various efflux 
proteins belonging to ABC transporter super family such as MDR1 137 and MRP-1 23 in 
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Calu-3 cells. Therefore, Calu-3 cell line has been selected as a model cell line to 
investigate the BCRP expression and to estimate its functional activity.   
 
Materials and Methods 
 Cell Culture 
           Calu-3 cells were cultured in DMEM-F12 medium supplemented with 10%  heat 
inactivated fetal bovine serum, MEM non-essential amino acids, HEPES, sodium 
bicarbonate, penicillin (100 µg/ml) and streptomycin (100 µg/ml). Cells were maintained 
at 37oC, in a humidified atmosphere of 5% CO2 and 90% relative humidity. Medium was 
replaced every alternate day until 5 days and subsequently every day until 11 days. Cells 
were subcultured by trypsinization with 0.25% trypsin containing 0.537 mM EDTA. 
 
RT-PCR 
              Isolation of total RNA from cells was carried out with Trizol-LS® reagent 
(Invitrogen) according to manufacturer’s instructions. RNA was mixed with 1.25 µl of 
oligo dT15 primer and denatured at 70oC for 10 minutes and 4oC for 5 minutes. Following 
denaturation, it was reverse transcribed to cDNA with 1 µl (10 units) of Moloney Murine 
Leukemia Virus Reverse Transcriptase (Promega, Madison, WI) per reaction mixture. After 
the first strand cDNA synthesis, 1 µl of cDNA was used for the PCR.  GAPDH and 
ABCG2 primers as shown in table-1 were designed using OligoPerfect™ Designer 
(Invitrogen Corp. Carlsbad, CA). Briefly, the PCR mixture was adjusted to a final 
112 
 
volume of 50 µl and contained template cDNA, 250 nM each of forward and reverse 
primers for the gene of interest, 1X Mg free PCR buffer (Promega), 3.75 mM MgCl2, 
0.025U Taq Polymerase (Promega), and 200 µM dNTPs, The polymerase chain reaction 
conditions consisted of denaturation at 94°C for 2 min, followed by 35 cycles of 94°C for 
30 s, 55°C for 30 sec and 72°C for 1 min with a final extension at 72°C for 10 min. Ten 
microliters of PCR products obtained from PCR were separated by 2% agarose gel in tris-
acetate-EDTA buffer along with 100 bp ladder. 
 
Table-5  PCR primers for GAPDH and ABCG2 
 
 
Western Blot Analysis 
              Calu-3 cells grown in culture flasks were washed with phosphate-buffered saline 
(PBS) three times for ten minutes each. Cells were scrapped and homogenized in lysis 
buffer (PBS without calcium and magnesium, 1% Triton-x and protease inhibitor 
cocktail). The lysate was kept on ice for 30 minutes and then homogenized. Cell lysate 
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was then centrifuged at 20,000 rpm for 10 minutes at 4°C. The supernatant was collected 
and stored at -80°C until further use. Protein content was measured with Bradford 
reagent. Three concentrations (25 µg, 50 µg and 75 µg) of protein were employed for gel 
electrophoresis. Protein samples were incubated at 100°C for 3 minutes and 15 µl sample 
was loaded onto a 4-12% NuPage Bis-Tris gel. Electrophoresis was carried out at 120V 
and subsequently transblotted at 15V for 90 minutes onto a polyvinylidene fluoride 
membrane. Blot was then blocked overnight with 3% nonfat dry milk and 1.5% bovine 
serum albumin. The membrane was incubated with BXP-21 monoclonal antibody (1:200 
dilution) for 2 hours at room temperature and then probed with secondary antibody 
tagged with horse radish peroxidase. Bands were visualized with ChemiImager 8900 
digital imaging system (Alpha Innotech, San Leandro, CA).  
 
 Immunocytochemistry 
            Calu-3 cells grown on slides were used for these studies.  Cells were washed with 
cold PBS for 10 minutes thrice and then fixed with 4% paraformaldehyde for 10 minutes. 
Fixed cells were washed and then permeabilized with 2% saponin and incubated for 2 
min at room temperature. Nonfat dry milk (3%) and bovine serum albumin (1.5%) were 
used for blocking for 2 hours. Membrane was incubated with mouse monoclonal 
antibody (BXP-21) for 2 hours. Following incubation with primary antibody, FITC 
tagged secondary antibody was added to cells and incubated for 1 hour at room 
temperature. For the negative control, slides without primary antibody were employed. 
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Mounting medium was then added to chamber slides without any air bubbles and then 
stored at 4°C until further use. Slides were visualized using a confocal fluorescence 
microscope.  
 
 Uptake Studies 
            At 11-13 days post seeding, cells were rinsed three times with DPBS (pH 7.4, 129 
mM NaCl, 2.5mM KCl, 7.4mM Na2HP04, 1.3 mM KH2PO4, 1 mM CaCl2, 0.7 mM 
MgSO4 and 5.3 mM glucose) and equilibrated for 15 minutes with the buffer. [3H]-
Mitoxantrone (166 nM) was used as a BCRP substrate to characterize functional activity. 
Time dependent uptake of [3H]-mitoxantrone was performed to determine the incubation 
time for all the studies. Uptake studies were performed by incubating a fixed amount of 
0.5 µCi/ml of [3H]-mitoxantrone alone and in the presence of BCRP inhibitors at 370C. 
GF120918 (0.5, 1 and 5 µM), quercetin (50 µM) and saquinavir (50 µM) were added as 
BCRP inhibitors to determine the functional activity of BCRP. Following incubation, the 
reaction was stopped by addition of ice cold stop solution (210 mM KCl, 2 mM HEPES; 
pH 7.4). After three washings with stop solution, cells were lysed by keeping them 
overnight in 1 ml of 0.1% Triton-X solution in 0.3% NaOH. Following overnight 
incubation, 500 µl of the cell lysate from each well was transferred to scintillation vials 
containing 5 ml of scintillation cocktail. Samples were analyzed by liquid scintillation 
counter and uptake was normalized to the protein content in each well. Amount of protein 
in the cell lysate was measured by the Bio-Rad protein estimation kit with bovine serum 
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albumin as standard. Functional activity of BCRP was assessed by studying the uptake of 
[3H]-mitoxantrone in the presence of 0.5, 1 and 5 µM GF120918.  
 
Hoechst 33342 Accumulation and Cytotoxicity Studies 
               Hoechst 33342, a fluorescent substrate was added to assess the efflux mediated 
by BCRP. Culture medium was first removed from the 96 well plates and washed with 
DPBS buffer at pH-7.4. Concentration dependent accumulation of Hoechst 33342 dye 
was measured to determine the experimental concentration for the remaining studies. 
Cells were incubated with varying concentrations of Hoechst 33342 dye ranging from 1 
µM to 100 µM for 15 minutes.  After 15 min incubation, reaction was arrested with stop 
solution (210 mM KCl and 2 mM HEPES; pH 7.4) and lysed with 1 ml of lysis buffer 
(0.1% Triton-X solution in 0.3% NaOH). Amount of intracellular dye was measured with 
a fluorescence spectrophotometer. Excitation and emission filters were set at 370 and 
450nm and the intracellular mean fluorescence was normalized to protein content. For the 
remaining studies, cells were incubated with 5 µM Hoechst 33342 (100 µl) in DPBS 
buffer with or without BCRP inhibitors GF120918 (5 µM and 10 µM) and fumitremorgin 
C (1 µM and 5 µM). Similarly, ATP dependent accumulation study of Hoechst 33342 
was performed in the presence of ouabain (1mM) and 2, 4, dinitrophenol (1 mM). 
Cytotoxicity studies of Hoechst 33342 dye alone and in the presence of BCRP inhibitors 
and ATP modulators was evaluated by MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl 
tetrazolium bromide] assay. 10 % DMSO was selected as a positive control for the 
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cytotoxicity studies. Cytotoxicity tests were performed according to manufacturer’s 
protocol. 
 
Statistical Analysis 
           All results were expressed as mean ± standard deviation. All the experiments were 
done in triplicate. Statistical analysis between two groups of data was carried out with a 
student’s t-test. A difference between mean values was considered significant at the P-
value less than 0.05.  
Results and Discussion 
              Pulmonary delivery has been utilized to administer several small molecule 
drugs, as well as therapeutic peptides and proteins. Small molecules delivered through 
inhalation route have higher bioavailability due to the lack of first pass metabolism and 
resistance to peptidases in the lungs. Lungs are constantly exposed to harmful xenobiotics 
and air borne toxins 147. Therefore, the organ displays protective efflux mechanisms to 
protect it from the external environment. Air-lung epithelial barrier is the most significant 
barrier to absorption for the inhaled drugs. Studies have shown that p-glycoprotein 
expressed in airway and bronchial epithelial cells is involved in the removal of 
environmental xenobiotics and cytotoxic drugs into the lumen and blood. Earlier studies 
from our lab have shown that p-glycoprotein limits the transport of anti-HIV protease 
inhibitors across Calu-3 cells (Patel et al., 2002). MRP1 has also been shown to be 
expressed on the basolateral side of the airway epithelium of the normal lung tissue.  
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However, BCRP expression in bronchial epithelial cells and its impact on the kinetics of 
inhaled drugs has not been investigated. 
             The present study provides the first evidence for the expression of BCRP across 
air-lung epithelial barrier. Calu-3 cell line has been validated as a metabolic and transport 
model to study the mechanisms of drug delivery at respiratory epithelium. Therefore, we 
selected Calu-3 cell line as a model cell line to investigate the BCRP expression studies. 
Previous studies have shown that Calu-3 cells exhibited higher TEER values and stable 
morphology between 11-13 days. Calu-3 cells grown for 11-13 days were used for the 
functional activity studies. 
  
Detection of ABCG2 mRNA Levels in Calu-3 Cells 
              RT-PCR was carried out to determine the ABCG2 mRNA levels in Calu-3 cells. 
RNA was extracted from Calu-3 cells grown in DMEM-F12 medium with 10% FBS 
using trizol reagent. RT was performed using MMLV-RT enzyme and RNA was reverse 
transcribed to cDNA. Resulting cDNA was used as a template for PCR reaction.  Primers 
specific to BCRP were designed using an Oligoperfect designer. GAPDH was used as an 
internal standard. Amplified PCR products obtained were separated by 2% agarose gel 
electrophoresis and bands were visualized. With BCRP specific primers, bands were 
detected at 508 bp following gel electrophoresis (Figure 6.1). Band for GAPDH was 
detected at 723 bp. 
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Figure 6.1  PCR image for ABCG2 
BCRP Protein Detection in Calu-3 Cells 
Western blot was performed to study the expression of BCRP protein in Calu-3 cells. 
BXP-21 a mouse monoclonal antibody raised against amino acids 271-396 of ABCG2 
was used for the western blot. BXP-21 does not cross react with other efflux transporters 
such as p-glycoprotein, MRP-2 and MRP-1. Western blot was performed to determine the 
expression of BCRP protein in Calu-3 cells. Protein samples were electrophoresed by 
SDS-PAGE and transferred to a PVDF membrane. BXP-21 monoclonal antibody was 
used to detect BCRP protein in Calu-3 cells. Lanes 2, 3 and 4 were loaded with 25, 50 
and 75 µg protein extracted from Calu-3 cells. Figure 6.2 illustrates the bands detected by 
chemiluminescence. Bands were observed at approximately 72 kDa corresponding to 
BCRP.  
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Figure 6.2   Western blot analysis of breast cancer resistance protein BXP-21 
monoclonal antibody was used to detect BCRP protein in Calu-3 cells. Lanes 2, 3 
and 4 were loaded with 25, 50 and 75 µg protein extracted from Calu-3 cells. 
 
Immunocytochemical Detection of BCRP 
 
Figure 6.3  Confocal microscopy of breast cancer resistance protein 
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BCRP expression was evaluated by immunocytochemical staining with a BXP-21 mouse 
monoclonal antibody. Calu-3 cells revealed strong plasma membrane localization (Fig. 
6.3). In addition, some cytoplasmic staining was also observed with the use of BXP-21. 
 
Uptake Studies with Radioactive Mitoxantrone 
           Time dependent uptake was performed to determine the uptake time for inhibition 
studies. Uptake of [3H]mitoxantrone was found to be linear for 30 minutes as shown in 
Figure 6.4. So, a 15 minute time period was selected for all subsequent inhibition studies. 
Uptake of [3H]mitoxantrone gradually increased significantly with increasing 
concentrations of GF120918.  
 
Figure 6.4  Time dependent study of [3H]mitoxantrone  
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As shown in Figure 6.5, uptake of [3H]mitoxantrone was found to be 112 ± 3.7%, 133 ± 
4.2%, 145 ± 11.7%  in the  presence of 0.5, 1 and 5 µM GF120918 respectively as 
relative to control. Quercetin (50 µM) and Saquinavir (50 µM) enhanced the uptake of 
mitoxantrone to 141 ± 3.7%, 193 ± 2.6% respectively as compared to control (Figure 
6.6). 
 
 
 
Figure 6.5   Concentration dependent study of [3H]mitoxantrone 
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Figure 6.6   Uptake of [3H]mitoxantrone in presence of BCRP inhibitors 
Hoechst 33342 Accumulation Studies 
              BCRP functional activity was evaluated by measuring the accumulation of 
Hoechst 33342 in Calu-3 cells. Concentration dependent accumulation of Hoechst 33342 
was also performed to select the 5 µM experimental concentration. ABCG2 specific 
inhibitors GF120918 and fumitremorgin C were selected for inhibition studies. As shown 
in Fig. 6.8, Hoechst 33342 uptake was found to be 168.37 ± 11.7%, 159.37 ± 7%, 150.49 
± 6.5% and 164.34 ± 7.23% as compared to control in the presence of 5 µM GF120918, 
10 µM GF120918, 1 µM fumitremorgin C and 5 µM fumitremorgin C. To study the 
energy dependency of  Hoechst 33342 dye, uptake of the fluorescent dye was performed 
in the presence of 1 mM ouabain (Na+ /K+ -ATPase inhibitor) and 1 mM 2, 4-
dinitrophenol (intracellular ATP reducer). 
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Figure 6.7   Concentration dependent study of Hoechst 33342 dye 
 
Figure 6.8  Hoechst 33342 uptake in presence of different concentrations of 
GF10218 and Fumitremorgin C 
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Figure 6.9   Energy dependent uptake of Hoechst 33342  
 
In presence of ouabain and 2, 4-dinitrophenol, Hoechst dye uptake enhanced significantly 
(Figure 6.9). Uptake was found to be 156.43 ± 12.76% and 175.68 ± 8.5% respectively in 
presence of 1 mM ouabain and 1 mM 2, 4-dinitrophenol.  
 
Cytotoxicity Studies 
             In the course of our studies, to determine whether the Hoechst 33342 dye, BCRP 
inhibitors and ATP modulators were cytotoxic to the cells, cytotoxicity studies were 
performed with MTT assay kit. Hoechst 33342 and the inhibitors were incubated with the 
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cells under the same conditions as the accumulation assay. Viability of Calu-3 cells was 
found to be unaffected in the presence of BCRP inhibitors and ATP modulators (6.10).  
 
 
Figure 6.10   Cytotoxicity in presence of BCRP inhibitors 
 
In our studies, radioactive mitoxantrone was used as a substrate to determine the 
functional activity of BCRP. Mitoxantrone had been shown to possess a high affinity 
substrate to BCRP and its accumulation correlated well with BCRP expression. Drug 
resistant cell lines that overexpress BCRP and cell lines transfected with BCRP cDNA 
were found to accumulate lower amounts of mitoxantrone 148. Radioactive mitoxantrone 
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has been used as a radiolabeled substrate for BCRP and incubated for 1.5 hours, 2 hours 
and 3 hours to determine the functional activity. Radioactive mitoxantrone was used 
alone and in the presence of BCRP specific inhibitors in these studies. Time dependent 
uptake of mitoxantrone was performed to determine the optimal time of incubation. 
Based on the results, 15 minute incubation was selected for all the experiments. Results 
from the uptake studies reveal that uptake of mitoxantrone was increased in presence of 
BCRP inhibitors GF120918, quercetin and saquinavir. GF120918 is a potent BCRP 
inhibitor with an IC50 value of 50 nM. Fumitremorgin c is a more specific and potent 
inhibitor for BCRP efflux pump than GF120918. Miscellaneous potent inhibitors such as 
flavanoids 149 and protease inhibitors 150  were also used to confirm the BCRP inhibition. 
Uptake increased significantly in the presence of BCRP inhibitors indicating the presence 
of functionally active BCRP. HIV protease inhibitors were found to be potent BCRP 
inhibitors and maximum concentration of saquinavir used for studies was 50 µM (Weiss 
et al 2004).  Zhang et al have shown that flavanoids strongly inhibited the BCRP 
mediated accumulation of mitoxantrone. Mechanism of interaction between BCRP and 
its substrates and inhibitors is very complex due to the presence of multiple binding sites 
on BCRP. Also, ATP hydrolysis is one of the major mechanism by which the inhibitors 
interact with BCRP. Flavanoids bind to the nucleotide binding domain of BCRP whereas 
mechanism of interaction between BCRP and HIV protease inhibitors is yet to be 
understood completely.   
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Litman et al correlated BCRP expression with reduced accumulation of several 
fluorescent drugs such as mitoxantrone, daunorubicin, bisantrene, topotecan, lysotracker 
and rhodamine 123 in BCRP overexpressing cells. P-gp and Mrp1 substrates were not 
effluxed from BCRP overexpressing cells which indicated the differentiation of BCRP 
mediated drug resistance. Kim et al studied the ability of BCRP to efflux the fluorescent 
dye, Hoechst 33342 in hematopoietic stem cells. In our studies, Hoechst 33342 dye 
accumulation assay was performed to determine the functional activity of BCRP.  
Hoechst 33342 was used at a concentration of 5 µM which when calculated was found to 
be approximately 3 µg/ml. Previous studies by Scharenberg et al and Kim et al used 
Hoechst 33342 dye at a concentration of 5 µg/ml and 4 µg/ml for BCRP mediated efflux 
studies. Concentration dependent accumulation studies of Hoechst 33342 varying from 1 
µM to 100 µM were done to select the experimental concentration within the linear 
range. A concentration of 5 µM Hoechst 33342 dye was selected for the fluorescent dye 
accumulation studies. Hoechst 33342 dye accumulation elevated significantly in presence 
of BCRP inhibitors such as GF120918 and fumitremorgin C. Fluorescent dye studies 
with ouabain and 2, 4-dinitrophenol indicated the energy dependent efflux of Hoechst 
dye in Calu-3 cells. These results suggest the involvement of energy dependent efflux 
process. MTT assay revealed the lack of toxicity of Hoechst 33342 alone and in the 
presence of BCRP inhibitors and ATP modulators to Calu-3 cells. 
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Conclusions 
In conclusion, our present study demonstrates for the first time the presence of BCRP 
expression and functional activity across human bronchial epithelial cell line, Calu-3. 
Further studies are needed to delineate the role of BCRP on the pharmacokinetics of 
inhaled drugs.  
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CHAPTER-7 
TO INVESTIGATE THE EFFECT OF CHRONIC NICOTINE EXPOSURE ON 
THE LEVELS OF EFFLUX TRANSPORTERS AND METABOLIZING 
ENZYMES IN CALU-3 CELLS AND RAT LUNGS 
 
Rationale 
           Lung cancer and AIDS are the major causes of morbidity all over the world. 
Nicotine is one of the most profoundly used addictive drugs in United States. According 
to world health organization, cigarette smoking is the foremost preventable cause of 
morbidity affecting almost one third of the global population.  Nonsmokers exposed to 
tobacco smoke are at a similar risk as that of a light smoker. Also, conditions of the 
adults with preexisting pulmonary conditions such as allergies, chronic lung diseases and 
other opportunistic life threatening infections are intensified by cigarette smoking. 
Previous research reports have shown that nicotine is linked with tumor promotion and 
resistance to therapy in lung cancer. There is limited information available about nicotine 
mediated induction of chemoresistance and hence there is a need to investigate the effect 
of chronic nicotine exposure. In case of HIV infection, it is important to treat the 
opportunistic infections and to monitor the clinical efficacy of pulmonary drugs and HIV 
protease inhibitors. Since, lungs are one of the primary sanctuary sites for HIV virus, this 
chapter aims to explore the chronic effect of nicotine on the levels of efflux transporters 
and metabolizing enzymes (CYP3A4/CYP3A5) in vitro and rat lungs. Also, role of 
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nuclear receptor PXR was investigated.  Recent research has shown that several protease 
inhibitors are successfully used in combination to treat lung cancer.  According to 
research by National Cancer institute, nelfinavir, saquinavir and ritonavir inhibited 
growth of lung cancer cells in vitro. Researchers investigated six different protease 
inhibitors in 60 human cancer cell types and mouse models. Results have shown that 
nelfinavir, ritonavir and saquinavir inhibited growth of non-small cell lung cancer. 
Interactions can be mediated by MDR1, MRP2 and BCRP efflux transporters and 
CYP3A4/CYP3A5 metabolizing enzymes expressed in lungs. Drug interaction uptake 
studies in Calu-3 cells (human bronchial cancer cells) in our laboratory demonstrated 
functional activity of efflux transporters such as MDR1 and BCRP in Calu-3 cells. 
CYP3A4/CYP3A5 expression was identified and functional activity of cortisol was 
established in Calu-3, rat lung and human lung microsomes. In view of the above 
observations, chronic nicotine exposure can play a significant role in induction of efflux 
transporters and metabolizing enzymes resulting in drug resistance and subsequent 
therapeutic failure.  
 
Introduction 
            Pulmonary drug delivery is a noninvasive route of drug delivery used for delivery 
of locally acting compounds as well as for the compounds targeting blood circulation. 
Pulmonary drug delivery is the ideal mode of delivery for rapid onset of action. Air borne 
suspension of fine particles are delivery by devices such as metered dose inhalers, 
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nebulizing solutions and dry powder inhalants. Lung is the only organ that receives the 
entire cardiac output. In order for the pulmonary drugs to reach their target, drugs has to 
cross the epithelial barrier in the lungs. Tracheal and bronchial epithelium constitutes the 
air way epithelium (Figure-7.1). Major cell types found in the lungs are ciliated 
columnar, goblet and basal cells. These ciliated columnar cells are responsible for the 
secretion of efflux proteins and also they have a higher cytochrome P450 metabolizing 
capacity.  
 
Figure 7.1   Anatomy of lungs 
Therapeutic management becomes difficult in treatment of diseases. Several protease 
inhibitors are recently being investigated for their use in cancer therapy. Ritonavir, 
saquinvir and nelfinavir inhibited growth of non-small cell lung cancer.   HAART 
therapy has been used for treatment of HIV infections. Patients are often treated for 
opportunistic infections of the lung. Drug interactions are often indicated for the 
pulmonary therapies. Rifampicin accelerates the metabolism of HIV protease inhibitors 
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resulting in sub therapeutic serum levels whereas protease inhibitors slow the metabolism 
of rifampicin leading to increased serum levels and cytotoxicity. Rate of smoking in HIV 
population is 57% higher than in general population (33%). In addition, smoking is the 
main risk for 87% of cases associated with lung cancer. Nicotine readily diffuses through 
skin, lungs and mucous membranes. It has a half-life of about 60 minutes. Nicotine is 
metabolized to cotinine and nicotine oxide by lungs. Thus, the purpose of this study was 
to investigate whether nicotine can induce the expression of efflux transporters and 
metabolic activity of CYP3A4.   
 
Materials and Methods 
Calu-3 Cell Culture 
            Calu-3 cell line, an airway epithelium derived cell line from human lung 
carcinoma was procured from ATCC. Calu-3 cells between passages 15-40 were 
employed for all the studies. Cells were cultured in DMEM-F12  supplemented with 10% 
heat inactivated fetal bovine serum, non-essential amino acids (NEAA), HEPES, sodium 
bicarbonate, penicillin (100units/ml) and streptomycin (100 µg/ml) were purchased from 
Sigma Chemical Co. Cells were maintained at 37oC, in a humidified atmosphere of 5% 
CO2 and 90% relative humidity. The medium was replaced every alternate day.  
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Preparation of Microsomes  
            Calu-3 cells grown for 11 days were washed thrice with phosphor buffered saline 
and scraped with a cell scrapper. The cell suspension was centrifuged at 1000 g and the 
pellet was suspended in cell homogenization buffer (50 mM Tris HCl buffer, pH-7.4, 
0.25 M sucrose, 1 mM EDTA and protease inhibitor cocktail). The suspension was then 
homogenized. Nuclear and mitochondrial fractions were removed after centrifuging the 
samples at 3000 g for 10 min.  
 
Figure 7.2  Microsomes extraction procedure  
 
Later mitochondrial fraction was discarded after centrifuging the sample at 9000 g for 20 
minutes. Supernatant obtained from the previous step was centrifuged at 105,000 g for 
one hour to obtain the microsomal pellet. Microsomal protein was stored at -80oc for 
further studies. Protein content of the microsomes was measured by adding Bradford 
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reagent. Microsomes were extracted after treating with nicotine for seven days according 
to the figure -7.2. 
 
Western Blotting 
            Whole cell protein was extracted with reagent containing 3.2 mM Na2HPO4, 0.5 
mM KH2PO4, 1.3 mM KCl, 135 mM NaCl, 1% Triton X - 100 and protease inhibitor 
cocktail at pH 7.4. Confluent cells were washed thrice with PBS and harvested using a 
cell scraper in 5 mL of PBS. The cell suspension was centrifuged at 1500 rpm for 10 
minutes and the pellet was resuspended in freshly prepared lysis buffer for 15 minutes on 
ice.  The extracted protein was then obtained by centrifugation and stored at -80oC, until 
used. Protein content was determined using Bradford method. Polyacrylamide gel 
electrophoresis (PAGE) was run with 25 and 50 µg of each protein at 120 V, 250 mAmp. 
Transfer was carried out on polyvinylidene fluoride (PVDF) membrane at 25 V for 1 h 30 
min, on ice. Immediately after transfer, the blot was blocked for 3 hours in freshly 
prepared blocking buffer (2.5 % non-fat dry milk and 0.25 % bovine serum albumin 
prepared in TBST pH-8). After a light wash for 10 sec, the blots were exposed to primary 
antibodies overnight. The blots were then exposed for 2 hours to secondary antibodies 
obtained from Santa Cruz Biotechnology. The blots were finally washed three times with 
TBST and developed using SuperSignal West Pico chemiluminescence substrate. The 
blots were exposed for 30 sec after which the image was taken in Gel Doc Imager. 
 
135 
 
Real Time PCR 
 RNA was extracted from the control and nicotine treated lung tissues using Trizol 
reagent (Invitrogen). All samples were normalized to 1 µg of total RNA. 1 µg of total 
RNA was mixed with 1.25 µl oligo dT primer at 70ºc for 10 minutes and then reverse 
transcribed to cDNA using MMLV-reverse transcriptase enzyme. Real time PCR was 
according to a standard protocol published by Roche. Real time PCR primers were 
designed using oligo perfect designer. All the primers were designed such that the 
amplicons generated were between 100-200 bp long to increase the efficiency of 
simultaneous amplification of target and reference genes. Briefly, the PCR mixture has a 
volume of 20 µl. SYBR green kit from Roche has 2X concentration of PCR master mix 
and PCR grade water. To this master mix, 250 nM each of forward and reverse primers of 
gene of interest were added. The master mix was then transferred to a multiwall plate.  5 
µg/µl cDNA sample was added to this master mix to prepare 20 µl of PCR sample. The 
samples were then carefully centrifuged at 3000 g for 2 minutes. Samples were analyzed 
and fluorescence was quantified. 
 
 Analysis 
 Samples for real time PCR were prepared in triplicate. Quantitative values were obtained 
above the threshold PCR cycle number (Ct) at which the increase in signal associated 
with an exponential growth for PCR products were detected. The relative mRNA levels 
in each sample were normalized according to the expression levels of β-actin. An 
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induction ratio(treated/untreated) was determined from the relative expression levels of 
the target gene using 2-∆Ct  (∆Ct =Ct target gene-Ct β-actin). The average of the real time 
PCR measurements were used to calculate the mean induction ratio for each gene.  
 
Cortisol Metabolism Studies 
            Cortisol was used as a model substrate to study the CYP3A4 mediated 
metabolism. 6-hydroxy cortisol was obtained from sigma. Briefly, microsomes isolated 
using standard methods were used for the metabolism studies. Fixed concentration of 
microsomal protein (0.5 mg/ml) was used for the studies. Microsomal protein solution  
(100 mM phosphate buffer (KH2PO4 100 mM and Na2HPO4, 2H2O 100 mM) at pH 7.4) 
containing 6 mM MgCl2  and 0.1 mM EDTA was incubated with NADP regenerating 
system ( 8 mM G6P, 0.1 UI/ml G6PD and 0.3 mM NADP+   for 5 minutes at 37 ºc. were 
in a final volume  of 1 ml. After activation, 200 µM cortisol was added to the above 
mixture and incubated for 30 minutes. The reaction was stopped by adding 500 µl 
methyl-tert-butyl ether. The sample was then vortexed and centrifuged at 10,000 g for 3 
minutes. The upper layer was then separated and evaporated. The residue was dissolved 
in 200 µl mobile phase for further HPLC analysis.  
 
HPLC Analysis of 6-hydroxycortisol 
            Analysis of 6-hydroxycortisol was performed according to published protocol. All 
samples will be analyzed by a reversed phase HPLC technique. A C8 Luna column (250 x 
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4.6mm; Phenomenex, Torrance, CA) was employed for the quantification of metabolites. 
Mobile phase composed of 0.5 % w/v Ammonium phosphate monobasic and acetonitrile 
(75:25 v/v) was used to elute the samples. Flow rate will be maintained at 0.8 mL/min 
and detection wavelength set at 254 nm. 
 
Rat Metabolism Studies 
           Human lung microsomes (10 mg/ml) obtained from smokers and nonsmokers 
were obtained from Xenotech LLC. Microsomes from control and nicotine treated rats 
were isolated from rat lungs. Microsomal protein concentration was obtained by Bradford 
reagent. Metabolism studies were performed according to the above mentioned protocol. 
 
Oral Rat Studies 
             Male Sprague-Dawley rats weighing 200-300 g were utilized for these studies. 
Rats were fasted overnight before treating them with control or drug solution. Nicotine 
solution (5 mg/kg in 0.8 ml sterile saline) was administered by oral gavage twice a day 
for 5 days. After five days of exposure to nicotine, tissues were isolated and stored at -
80ºc for further use. 
Results and Discussion 
             Majority of the inhaled toxicants pass through the respiratory tract, exposing 
pulmonary epithelium to higher concentrations than liver cells. Higher concentrations can 
contribute to significant metabolism in lungs. In the same way, higher concentrations of 
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tobacco smoke can modulate the metabolism of CYP enzymes.  Several CYP enzymes 
are expressed in the lungs of mammals, but studies on their modulation are very limited.  
              Role of pulmonary metabolism in the systemic clearance of the xeniobiotics has 
not been well studied. Total cardiac output reaches the lungs and therefore, systemic 
drugs can be metabolized in lungs. Pulmonary alveolar epithelium has a larger surface 
area and inhaled drugs are exposed to pulmonary enzymes resulting in significant 
metabolism. Expression of PXR and CAR was detected in human lungs 
 
Expression of CYP3A4 and PXR mRNA expression 
              RT-PCR was performed to determine the mRNA expression in Calu-3 cells, rat 
lungs and normal lungs. Analysis showed that CYP3A4 was expressed in all the three 
tissues, Calu-3, rat lungs and human lungs at 500 bp (Figure-7.3). Strong expression of 
CYP3A4 was observed in human lung tissue when compared to Calu-3 cells and rat 
lungs.   
  
Figure 7.3  CYP3A4 mRNA expression in Calu-3 cells, rat lungs and human lungs 
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Nuclear Receptor Expression in Calu-3 Cells 
             PXR expression was confirmed in Calu-3 cells. PCR products obtained by using 
specific primers were detected at 320 bp (Figure-7.4). In another set of experiments, 
PXR, CAR and RXR expression was analyzed. Results from this experiment indicated 
the presence of PXR and RXR mRNA in Calu-3 cells. CAR expression was not detected 
in our experiment (figure-7.5).  
 
 
 
Figure 7.4   PXR expression in Calu-3 cells 
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Figure 7.5   Nuclear receptors (PXR, CAR and RXR) mRNA expression in Calu-3 
cells 
 
Semi quantitative PCR was performed to quantify CYP3A4 mRNA levels in nicotine and 
rifampicin treated Calu-3 cells. Since we were not able to quantify by this method, real 
time PCR was later performed to study the induction levels (figure-7.6).   
 
Figure 7.6  Semi quantitative RT-PCR analysis of CYP3A4 mRNA expression in 
Calu-3 cells after treatment with nicotine and rifampicin  
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CYP3A4 Protein Expression  
             Western blot analysis indicated enhanced CYP3A4/CYP3A5 expression in rat 
lungs when compared to Calu-3 cells. Furthermore, strong CYP3A4/CYP3A5 protein 
expression was observed in nicotine treated lung microsomes. These results indicate 
induction of CYP3A4/CYP3A5 protein expression after treatment with nicotine. 
 
 
Figure 7.7   Immunoblot for CYP3A4 expression in Calu-3 cells  
 
Real Time PCR Studies to Quantify MDR1 and ABCG2 mRNA 
             Calu-3 cells exposed to nicotine for 72 hours were used for real time PCR 
studies. MDR1 mRNA levels enhanced significantly when Calu-3 cells were exposed to 
nicotine. Both the nicotine concentrations (2.5 µM and 10 µM) had significant induced 
mRNA levels by 2 to 3 fold approximately when compared to control (figure-7.8). 
ABCG2 mRNA levels were enhanced by 2 fold when compared to control (figure-7.9). 
 Rifampicin, a positive control for MDR1 and CYP3A4 induction also showed the 
induction in Calu-3 cells. Higher concentrations of nicotine enhanced CYP3A4 and 
CYP3A5 mRNA levels (figure 
 
 
 
Figure 7.8   Quantification of MDR1 mRNA protein expression in 
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Figure 7.10   Quantification of CYP3A4 and CYP3A5 mRNA protein expression in 
Calu-3 cells.  (N1 and N2 indicates 2.5 µM and 10 µM for nicotine, RF indicates 25 
µM for rifampicin)   (* indicates significant difference compared to control; p<0.05, 
n = 3 ± S.D)  
PXR Induction in Calu-3 Cells 
PXR mRNA was quantified in nicotine treated Calu-3 cells. As shown in figure 
7.11, PXR mRNA levels were enhanced by 4 and 15 fold respectively with nicotine 2.5 
µM and 10 µM concentrations.        
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Figure-7.11 PXR quantification in Calu-3 cells 
 
Cortisol Metabolism Studies 
              The 6β-hydroxylation of cortisol was used as a control to investigate the 
CYP3A4/A5 activity. Increased amount of metabolite 6β-hydroxycortisone was observed 
in nicotine treated rat lung microsomes. Concentration of 6β-hydroxycortisone was found 
to be 1.55 ± 0.16 nmoles/min.mg protein whereas concentration of 6β-hydroxycortisone 
was found to be 3.93 ± 0.61 nmoles/min.mg protein in nicotine treated rat lung 
microsomes. CYP3A4 mediated metabolism activity was found to be significantly higher 
in smokers when compared with nonsmokers (figure-7.13).  Human lung microsomes 
obtained from smokers (2.67±0.43 nmoles/min.mg protein) showed higher activity than 
lung microsomes obtained from nonsmokers (0.78 ± 0.36 nmoles/min.mg protein) 
(figure-7.14). 
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Figure 7.12  Rate of 6β-hydroxycortisone metabolite formation from cortisol in rat 
lung, human lung and human intestine microsomes 
 
 
Figure 7.13   Rate of 6β-hydroxycortisone metabolite formation from cortisol in 
microsomes obtained from non-smokers and smokers 
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Therefore, these results clearly suggested upregulation of CYP3A4 mRNA and protein 
expression after treatment with nicotine. This upregulation was further confirmed by 
enhanced CYP3A4 activity. However, more studies have to be performed to delineate the 
difference in CYP3A4 and CYP3A5 activity and expression. Although, both CYP3A4 
and CYP3A5 isoenzymes have same substrate specificity, they have different km values 
for substrates. To elucidate the mechanism and interplay between CYP3A4 and CYP3A5, 
expression and induction of gene regulatory elements for these isoenzymes need to be 
studied.   
 
Figure 7.14  Rate of 6β-hydroxycortisone metabolite formation from cortisol in rat 
lung microsomes from control rats and nicotine treated rat lungs 
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Conclusions 
               Upregulation of MDR1, ABCG2 and CYP3A4/A5 mRNA levels was observed 
after exposing cells to nicotine. This may suggest the possibility of modulation of efflux 
transporters and metabolizing enzymes by inhaled xeniobiotics. Cigarette smoking can 
alter the permeability and metabolism of inhaled drugs and thereby, reduce their efficacy. 
Furthermore, nuclear receptor PXR activation by nicotine can play a significant role in 
the induction of metabolism in lungs.     
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Chapter-8 
SUMMARY AND RECOMMENDATIONS 
Summary 
The objective of this study was to evaluate the effect of chronic treatment with 
morphine and nicotine on the expression of efflux transporters (MDR1, MRP2 and 
BCRP) and metabolizing enzymes (CYP3A4) in LS180, Caco-2 and HepG2 cells. 
Furthermore, the chronic effect of morphine and nicotine on the intracellular 
accumulation of model HIV protease inhibitors was determined.  
              In the third chapter, RT-PCR and Western blot studies were performed to 
quantify the expression of efflux transporters. Differential induction of MDR1, MRP2 
and ABCG2 mRNA levels was observed when LS180 and Caco-2 cells were exposed to 
morphine and nicotine. Intracellular accumulation of the model radioactive substrates 
was reduced following treatment. Morphine and nicotine induced signaling of efflux 
transporter gene expression can act as significant stimulators of efflux function. 
Morphine and nicotine activation of PXR can explain the induction of these efflux 
transporters and metabolizing enzymes. Due to the enhanced efflux transporter and 
CYP3A4 gene expression observed after the chronic treatment with morphine and 
nicotine, there could be potential drug-drug interactions with HIV protease inhibitors that 
are substrates for the efflux transporters and that are metabolized via CYP3A4. There 
could be alternate pathways involved in the failure of clinical HIV therapy based on these 
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results. Regular monitoring of plasma concentrations of HIV protease inhibitors are 
recommended in chronic nicotine and morphine abusers.   
                   Since nicotine is smoked through lungs, chronic effect of nicotine on the 
expression and activity of efflux transporters needs to be investigated. Lungs are one of 
the primary sanctuary sites for HIV viruses and opportunistic infections of the lungs are 
most commonly prevalent infections associated with HIV. Pulmonary drugs are widely 
prescribed along with anti HIV agents and these combinations can result in drug-drug 
interactions resulting in therapeutic failure. There is limited information known about the 
expression and functional activity of influx and efflux transporters in lungs  
            In the fourth chapter, expression and activity of folic acid carriers was 
investigated in human bronchial epithelial cell line, Calu-3. Our studies demonstrated the 
expression and functional activity of PCFT and FR-α receptor in Calu-3 cells. Also, the 
folic acid carriers were characterized and their functional activity was determined by 
employing [3H] folic acid.   
               In the fifth chapter, efflux transporter MRP2 expression in Calu-3 cells was 
studied in Calu-3 cells. RT-PCR studies demonstrated the presence of MRP2 expression 
in Calu-3 cells. Model MRP2 substrates and HIV protease inhibitor   [3H]ritonavir was 
utilized to determine the functional activity of MRP2. Apical to basolateral and 
basolateral to apical transport studies confirmed the presence of MRP2 mediated efflux of 
ritonavir. 
151 
 
                  In the sixth chapter, BCRP was identified and characterized in Calu-3 cells. 
Uptake studies were performed using model substrates for BCRP, mitoxantrone and 
Hoechst 33342 dye.  
                   In the seventh chapter, chronic effect of nicotine on MDR1, CYP3A4 and 
ABCG2 expression levels was studied after treating Calu-3 cells with nicotine. Nicotine 
induced MDR1, CYP3A4 and ABCG2 mRNA levels following treatment. Furthermore, 
nicotine induced cortisol metabolism in lung microsomes obtained from rats treated with 
nicotine when compared to control rats. Most of the inhaled compounds have a longer 
retention time resulting in significant contribution to efflux and CYP3A4 metabolism. 
Modulation of efflux transporters and CYP3A4 metabolism can play an important role in 
the absorption of inhaled rugs. These results conclude that chronic nicotine exposure can 
alter the disposition of inhaled drugs and there is a possibility of occurrence of drug-drug 
interactions in clinical setting.    
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Recommendations 
Finding a better inexpensive in vitro drug interaction model is essential to study the 
mechanisms of drug-drug interactions mediated by efflux transporters and metabolizing 
enzymes. New drug entities are often screened for their potential to interact with efflux 
transporters and metabolizing enzymes. There is an obvious need to study the role of 
efflux transporters and metabolizing enzymes to establish their role in disposition of anti 
HIV drugs. There is a need to study the role of chronic nicotine treatment on the 
pulmonary drug absorption for local and systemic action. This information could be 
extremely valuable in the preclinical prediction of drug absorption at the target of action.   
 Evidence of transporter mediated drug disposition in lungs in vivo needs to be 
investigated. There are no adequate in vitro and in vivo studies currently 
available to study the contribution of efflux transporters in lungs. Also, the lack 
of proper in vivo model and complexity of the current in vivo models pose several 
drawbacks in predicting the pulmonary bioavailability.   
 Contribution of nicotine to the disposition of inhaled drugs needs to be studied in 
vivo because of stronger induction effect of nicotine on efflux transporters.  
 More studies are to be designed to help us understand the in vivo modulation of 
efflux transporters in lungs and their contribution to physiology of pulmonary 
diseases. 
 Induction results confirmed the role of PXR in MDR1 and CYP3A4 mediated 
induction. However, expression and activation of CAR, aryl hydrocarbon receptor 
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(AhR) needs to be investigated. Further, computer docking studies and functional 
activation assay of AhR can give a better understanding of higher BCRP 
induction by morphine and nicotine.  
 Mechanism of drug interactions between drugs of abuse and HIV protease 
inhibitors should be studied in clinical settings and role of efflux transporters and 
nuclear receptors should be investigated. 
 Finally, more studies should be designed to study the relation between induction 
of efflux transporters and nuclear receptors and their contribution to anti HIV 
drug resistance. 
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